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The absence of an animal model for sporadic Inclusion Body Myositis (IBM) has hindered 
progress in the field including an incomplete understanding of pathogenesis and a lack of 
effective therapies. We have developed a novel xenograft model of IBM in which human skeletal 
muscle is transplanted into immunodeficient NOD-Rag1nullIIL2rγnull mice. These grafts are 
spontaneously revascularized and innervated by the mouse host to form a fully functional 
human muscle ideal for modeling disease.  At 4 months, xenografts from control and IBM 
patients both display robust regeneration, indicating that IBM patient satellite cells can 
proliferate and differentiate normally. In addition, pathological features of IBM are recapitulated 
within xenografts, including endomysial inflammation, primary invasion of non-necrotic fibers by 
CD3+ T cells, upregulation of MHC-I, and COX-deficient fibers. Ki-67 staining reveals that a 
majority of the CD8+ T cells within IBM xenografts are proliferative at 4 months, and T cell 
receptor sequencing shows that these T cells are oligoclonal. Removal of CD3+ T cells via 
treatment of mice with a monoclonal CD3 antibody (OKT3) does not significantly impact 
regeneration, indicating that myofiber regeneration is largely unaffected by T cells within 
xenografts. However, OKT3 significantly reduces the number of COX-deficient fibers suggesting 
that T-cell mediated inflammation drives mitochondrial pathology. Indeed, the number of COX-
deficient fibers is significantly correlated with the number of CD3+ T cells in IBM xenografts but 
not in control myositis xenografts with comparable numbers of T cells. In addition to these 
inflammatory features, splicing defects due to loss of nuclear TDP-43 and rare fibers containing 
p62-positive aggregates are observed at later timepoints (8-10 months). Thus, this xenograft 
model of IBM shows both inflammatory and degenerative features of the human disease, and 
this model will be valuable for carrying out mechanistic studies and preclinical therapeutic 
testing in IBM.   
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Chapter 1: Introduction 
 
“It’s not life-threatening, it’s life-changing.” 
-Peter Frampton, 2019 
 
When Peter Frampton publicly announced his diagnosis of Inclusion Body Myositis (IBM) 
in 2019, he shined a spotlight on this rare disease, which affects ~50 patients per million 
according to a recent meta-analysis study (Callan et al. 2017). IBM is a chronic disease 
of progressive skeletal muscle weakness with both degenerative and autoimmune 
pathological features. The field of IBM research faces many challenges, such as the 
uncertain pathogenesis, a struggle to develop effective treatments, and the lack of 
awareness in the general population as well as the medical community. A brief history of 
IBM, its clinical and pathological presentation, laboratory models, and treatment 
approaches for this life-changing disease are discussed below.  
1.1 History of Inclusion Body Myositis 
The first published description of IBM resides within a case study of a 66 year old man 
erroneously diagnosed with chronic polymyositis (PM) (Chou 1967). This patient 
presented with progressive weakness of all muscles over the course of 6 years, mild 
dysphagia, and muscle atrophy of the shoulder girdle and quadriceps. Of note, there 
was no significant elevation of creatine kinase (CK), whereas CK levels in PM patients 
are typically elevated 10-50 fold (Schmidt 2018). In hindsight, it is clear this study 
describes an IBM patient. A major novel finding of this study was the detection of 
filamentous aggregates via electron microscopy in both the sarcoplasm and nucleus of 




patient myofibers. Based on the morphological similarity of the filaments to structures 
observed in cultured myxovirus-infected cells, it was hypothesized that the patient’s 
disease was caused by a viral infection. In subsequent years, numerous studies have 
explored the association and potential contribution of viral infections to the development 
of IBM (Nishino, Engel, and Rima 1989; Kallajoki et al. 1991; Fox et al. 1996; Uruha et 
al. 2016). 
 
A case study from 1971 is responsible for the etymology of ‘Inclusion Body Myositis’, 
although, this study actually described a patient that likely had limb-girdle muscular 
dystrophy (Yunis and Samaha 1971). It took an additional seven years for the first 
‘accurate ‘ clinical case study of IBM to be published (Carpenter et al. 1978). In this 
study, 6 patients were described showing progressive muscle weakness frequently 
involving distal muscles, a male predominance, and no improvement with corticosteroid 
treatment. Pathologically abnormal filaments could also be detected in the muscle using 
electron microscopy, and “hematoxylinophilic granules in “lined” vacuoles”—rimmed 
vacuoles—were described for the first time (Carpenter et al. 1978). This case study 
established IBM as a discrete entity within the group of idiopathic inflammatory 
myopathies (IIM). IIM is a heterogeneous group of diseases characterized by skeletal 
muscle weakness, and the intramuscular infiltration of immune cells (Dalakas 2015). 
Currently, this group also includes Dermatomyositis (DM), Polymyositis (PM), Immune 
Mediated Necrotizing Myopathy (IMNM), and non-specific myositis (Hoogendijk et al. 
2004; Dalakas 2015). From these initial descriptions, the characteristics of IBM have 
been further researched and refined.  




1.2 The Presentation of Inclusion Body Myositis 
IBM patients have a heterogeneous presentation, and diagnosis is rarely straightforward 
with almost half of patients initially misdiagnosed with polymyositis, peripheral 
neuropathy, or motor neuron disease (Rose and ENMC 2013; Paltiel et al. 2015). 
Patients typically seek medical care when their muscle weakness limits the use of their 
hands or when they start to have difficultly climbing stairs or falls (Paltiel et al. 2015). 
The median time from symptom onset to diagnosis is between 5 to 6 years, and patients 
lose the ability to independently ambulate an average of 15 years after diagnosis 
(Needham, Corbett, et al. 2008; Molberg and Dobloug 2016). The diagnosis of IBM 
requires a careful assessment of a patient’s clinical features, which commonly includes 
physical exam, electrodiagnostic testing, blood testing, and in some centers, MRI of 
affected muscle groups. In addition, a thorough pathological analysis of a skeletal 
muscle biopsy is typically an important component of the diagnostic process.   
 
Clinical Presentation 
IBM has a male predominance and usually affects individuals over the age of 45 with a 
mean age of symptom onset between 61-68 years (Molberg and Dobloug 2016; Suzuki 
et al. 2016; Greenberg 2019). The disease is characterized by chronic, slowly 
progressive asymmetric weakness of both proximal and distal muscles, with the finger 
flexors and quadriceps typically most affected (Griggs et al. 1995). Dysphagia is 
observed in more than half of patients, with some studies reporting an incidence of 
greater than 80% (Wintzen et al. 1988; Houser, Calabrese, and Strome 1998; Mohannak 
et al. 2019). Cardiac abnormalities in IBM patients have not been extensively explored, 
but several studies suggest that cardiac function is largely unaffected. (Cox et al. 2010; 




Rosenbohm et al. 2020). However, patients with IBM may be predisposed to 
hypertension and show higher rates of myocardial infarction and congestive heart failure 
(Keshishian et al. 2018; Rosenbohm et al. 2020).  
 
MRI studies of IBM patients show fatty infiltration and inflammation in affected muscles, 
especially in the flexor digitorum profundus (FDP), vastus medialis and lateralis, and 
gastrocnemius (Phillips et al. 2001; Cox et al. 2011; Guimaraes et al. 2017; Ansari et al. 
2020). Assessment of FDP via MRI, electromyography (EMG), or ultrasonography may 
be particularly helpful in discriminating IBM from other IIMs and aid in diagnosis (Sekul, 
Chow, and Dalakas 1997; Hokkoku et al. 2012; Albayda et al. 2018). In contrast to the 
other forms of IIM, it is rare to observe a serum CK level more than 15 times the upper 
limit of normal (Rose and ENMC 2013). Another feature of IBM that distinguishes it from 
other IIMs are neurogenic findings in over 20% of IBM patients, including neuropathic-
like recruitment patterns on EMG (Felice and North 2001; Hermanns, Molnar, and 
Schroder 2000). The most important clinical features in establishing a diagnosis are the 
history and pattern of weakness on physical exam, with finger flexor weakness greater 
than arm abductor weakness and knee extensor weakness greater than hip flexor 
weakness.  In combination, these clinical features alone can be sufficient for a diagnosis 
of IBM by some diagnostic criteria. This has led some clinicians to question the 
necessity of a diagnostic open muscle biopsy, however, biopsies are routinely performed 
on IBM patients as they show several distinguishing pathological features and can be 









The pathological features of IBM are diverse and, although these features are shared 
with other disorders, in combination, they are highly specific for IBM. Histological 
features observed in IBM muscle biopsies include rimmed vacuoles, protein aggregates, 
cytochrome c oxidase (COX)-deficient fibers, upregulation of major histocompatibility 
complex class I (MHC-I) molecules, and an endomysial inflammatory infiltrate (reviewed 
in:Naddaf, Barohn, and Dimachkie 2018; Greenberg 2019). A considerable effort has 
been put forth by researchers to characterize the variety of aggregated proteins, and by 
2010 more than 80 proteins had been reported as present within aggregates in IBM 
patient muscle, including ubiquitin, tau, and β-amyloid (Greenberg 2010b). In this 
overabundance of aggregated proteins, TDP-43 and p62 have been suggested to have 
high specificity for IBM and are seen aggregated in a high percentage of fibers (Dubourg 
et al. 2011; Hiniker et al. 2013).  
 
Mitochondrial pathology has been recognized as a prominent feature of IBM, including 
myofibers that accumulate abnormal mitochondria, COX-deficient fibers, and 
mitochondrial DNA (mtDNA) deletions and depletion (Oldfors et al. 1993; Oldfors et al. 
2006; Lindgren et al. 2015; Bhatt et al. 2019). While the number of COX-deficient fibers 
normally increases with age, the proportion of COX-deficient fibers is significantly higher 
in IBM patients (Oldfors et al. 1993). Electron microscopy of affected muscle shows 
enlarged mitochondria, loss of inner membrane cristae, and paracrystalline inclusions, 
although, is it important to note these changes are also associated with normal aging 
(Oldfors et al. 2006). Decreased transcript and protein levels of mitofusion-2 (MFN2) and 
optic atrophy 1 (OPA1)—genes involved in mitochondrial fusion—in IBM muscle suggest 
fusion is impaired and may partially explain this altered mitochondrial morphology 




(Catalan-Garcia et al. 2016). In addition to these morphological changes, downregulated 
expression of complex I (NADH coenzyme Q oxidoreductase) and reduced COX activity 
indicates impaired oxidative phosphorylation in IBM muscle (Lindgren et al. 2015; Rygiel 
et al. 2015). Interestingly, positive correlations have been reported between the number 
of COX-deficient muscle fibers and the relative amount of mtDNA deletions as well as 
the severity of inflammation (Lindgren et al. 2015; Rygiel et al. 2015). These studies 
suggest that mitochondrial pathology may be mechanistically linked with inflammation. It 
is possible that inflammatory cells could trigger mtDNA damage, eventually leading to 
respiratory dysfunction and subsequent degeneration of muscle fibers.  
 
The invasion of non-necrotic fibers by autoaggressive cytotoxic CD8+ T cells is a 
prominent feature of IBM muscle biopsies, and this inflammatory infiltrate has been a 
focus of numerous studies. T cell receptor (TCR) sequencing or spectratyping of cells 
from patient blood and muscle has shown these populations of T cells are clonally 
expanded, suggesting recognition of an unknown antigen is occurring (Amemiya 2000; 
Müntzing et al. 2003; Salajegheh et al. 2007). Recent microarray and mass cytometry 
studies have revealed a distinctive signature of T cell cytotoxicity in IBM muscle and 
blood in comparison to other muscle diseases and an abundance of highly differentiated 
CD8+ T-cell effector memory (TEMRA) cells and terminally differentiated effector cells 
(Greenberg et al. 2019; Dzangue-Tchoupou et al. 2019). This cytotoxic signature shows 
elevation of granzymes A, B, H, and K, perforin, and increased expression of KLRG1 
(killer cell lectin-like receptor G1) and T-bet (T-box expressed in T cells) which are 
markers of highly differentiated CD8+ T cells. KLRG1 is an inhibitory T- and NK-cell 
receptor associated with increased cytotoxic activity, and high levels of T-bet are 
required for antigen-specific CD8+ response and cytotoxic function (Hruz et al. 2008; 




Greenberg et al. 2019; Dzangue-Tchoupou et al. 2019). In particular, KLRG1+ cells were 
shown to be present in multifocal endomysial infiltrates and observed invading muscle 
cells. Taken together, KLRG1 and T-bet may serve as useful biomarkers for IBM, and it 
is hypothesized that therapeutic targeting of these highly differentiated cytotoxic T cell 
populations may be beneficial for the treatment of IBM. 
 
Beyond cell-mediated immune responses, microarray analysis of IBM patient muscle 
has revealed an overabundance of immunoglobulin gene transcripts and intramuscular 
CD138+ plasma cells, suggesting a previously unappreciated role of humoral immune 
mechanisms in IBM (Greenberg et al. 2005). In 2011, the first circulating autoantibody in 
IBM was discovered, and shortly thereafter two groups independently identified cytosolic 
5′‐nucleotidase 1A (NT5C1A; cN1A) as the target of this circulating autoantibody 
(Salajegheh, Lam, and Greenberg 2011; Larman et al. 2013; Pluk et al. 2013). These 
initial studies showed that serum positivity of anti-NT5C1A was highly specific—90-95%-
-for the diagnosis of IBM. Further analysis of additional patient cohorts have supported 
this high specificity, but the sensitivity varies widely from 37% to 76% (Greenberg 2014; 
Lloyd et al. 2016; Amlani et al. 2019). Part of this variation could be explained by the 
different tests used to detect anti-NT5C1A, and the antibody has also been detected in 
other disorders such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome at 
varying levels of prevalence (Rietveld et al. 2018). Overall, serum negativity for anti-
NT5C1A should not discourage a diagnosis of IBM, and more studies are needed to 
determine the diagnostic utility of anti-NT5C1A in IBM.  
 
Diagnostic Guidelines  
The first diagnostic criteria proposed by Griggs et al relied heavily on the pathological 




features of IBM and divided patients into two categories: definite or possible IBM (Griggs 
et al. 1995). A definite diagnosis of IBM required muscle biopsies to show all the 
following: mononuclear cell invasion of non-necrotic muscle fibers, vacuoles, and 
amyloid deposits or 15-18 nm tubulofilaments. If a muscle biopsy showed these features 
the patient would be diagnosed with definite IBM regardless of any other clinical or 
laboratory features. If a patient biopsy only showed invasion of mononuclear cells, then 
a combination of clinical and laboratory features would allow a diagnosis of possible 
IBM. Understandably, these strict criteria lacked sensitivity as one or more of these 
pathological features are often missing in IBM biopsies (Chahin and Engel 2008; 
Ikenaga et al. 2017). Therefore, an international group of experts met to review and 
update diagnostic criteria for IBM and established the ENMC IBM Research Diagnostic 
Criteria 2011 (Rose and ENMC 2013). 
 
The ENMC 2011 criteria divides IBM diagnosis into three classifications: clinico-
pathologically defined IBM, Clinically defined IBM, or Probable IBM. Unlike the Griggs 
criteria, this updated classification considers the patient’s clinical presentation. To be 
diagnosed with clinico-pathologically defined IBM patients must meet the following 
criteria: they must be over the age of 45, have a serum CK less than 15 times the upper 
limit of normal, with finger flexor and/or knee extension muscle weakness lasting more 
than a year, and muscle biopsies showing endomysial inflammation, rimmed vacuoles, 
and protein aggregation or 15-18nm filaments (Rose and ENMC 2013). Assessment of 
ENMC 2011 diagnostic criteria via machine learning approaches showed its “Probable 
IBM” classification performed the best with 90% sensitivity and 96% specificity (Lloyd et 
al. 2014).  The Probable IBM classification requires patients to be over the age of 45, a 
serum CK less than 15 times the upper limit of normal, with finger flexor or knee 




extension muscle weakness lasting more than a year, and muscle biopsies showing one 
or more of the following: endomysial inflammation, upregulation of MHC-I, rimmed 
vacuoles, or protein aggregation/15-18nm filaments (Rose and ENMC 2013). 
 
More recently, the European League Against Rheumatism (EULAR) and the American 
College of Rheumatology (ACR) has developed a new classification criteria for IIMs 
(Bottai et al. 2017). When using muscle biopsy features in combination with clinical 
factors the EULAR/ACR criteria had high sensitivity (93%) and high specificity (88%), 
and by comparison the ENMC 2011 had low sensitivity despite its high specificity. 
Needless to say, as research progresses new criteria will continue to be proposed with 
the goal of improving the diagnostic process for both patients and clinicians.  
1.3 Genetics of Inclusion Body Myositis 
This section is adapted from Britson, K.A., Yang, S.Y., and Lloyd, T.E. New 
Developments in the Genetics of Inclusion Body Myositis. Curr Rheumatol Rep. 2018 
Apr 2;20(5):26. doi: 10.1007/s11926-018-0738-0 (Britson, Yang, and Lloyd 2018). 
 
Introduction 
In 1990, IBM was referenced in 11 citations in the PubMed database maintained by the 
United States National Library of Medicine at the National Institutes of Health (Pubmed 
2020). Over the last decade the average number of citations has risen to 85 per year. 
Part of this growth can be attributed to the increasing number of sequencing studies 
performed on IBM patient samples, which has been made possible by a concerted effort 
by several international groups to develop patient biospecimen banks and databases of 




clinical information. Two groups that have been instrumental in these efforts are the 
Myositis Genetics Consortium (MYOGEN) and the International IBM Consortium Genetic 
Study (IIBMCGS).  
 
At this point, it is crucial to draw a distinction between IBM and hereditary Inclusion Body 
Myopathies (HIBMs). The latter is a group of genetic muscle disorders with either 
autosomal recessive or dominant inheritance, and includes Glucosamine (UDP-N-
acetyl)-2-epimerase/N-acetylmannosamine kinase gene (GNE) myopathy, hereditary 
inclusion-body myopathy with Paget's disease of the bone and frontotemporal dementia 
(IBMPFD), and HIBM with congenital joint contractures and external ophthalmoplegia  
(Broccolini and Mirabella 2015). Although rare patients with genetic muscle disease 
have been reported with clinical phenotypes indistinguishable from IBM (Roda et al. 
2014), HIBMs typically present at a younger age than IBM (before age 40), lack 
inflammation, and display different patterns of muscle weakness (Leung et al. 2014; 
Broccolini and Mirabella 2015). For example, GNE myopathy—also called HIBM2—is 
caused by autosomal recessive inheritance of mutations in the GNE gene, the 
quadriceps is typically spared, and biopsy shows rimmed vacuoles and protein 
inclusions but lacks inflammation (No et al. 2013; Huizing et al. 2014; Carrillo, Malicdan, 
and Huizing 2018). Thus, mutations in known HIBM genes cause syndromes that share 
degenerative features on biopsy but otherwise are clinically distinct from IBM. However, 
classic IBM can occasionally be present within multiple family members (“familial IBM”) 
strongly supporting a role for genetic risk factors in the development of IBM (Sivakumar, 
Semino-Mora, and Dalakas 1997; Ranque-Francois et al. 2005). The advent of high-
throughput sequencing technologies and the efforts of genetic consortiums have begun 
to shed light on the complex genetic landscape of IBM. 




HLA Locus: the strongest risk alleles for IBM 
Robust, unbiased genome-wide association studies (GWAS) have not yet been 
completed in IBM due to the rarity of the disease, though a large multinational effort is 
underway (Gang, Bettencourt, Houlden, et al. 2015).  Nonetheless, since first described 
by Garlepp et al in 1994, the Human Leukocyte Antigen (HLA) locus has been shown 
repeatedly to contain the strongest risk alleles for the development of IBM (Garlepp et al. 
1994; Rojana-udomsart et al. 2012; Johari et al. 2017; Rothwell et al. 2017). Recently, 
the Myositis Genetics Consortium (MYOGEN) analyzed immune-related genes in 252 
Caucasian IBM patients and 1,008 ethnically-matched controls from 11 countries using 
the Illumina Immunochip array (Rothwell et al. 2017).  Variants within the HLA locus 
were the only single-nucleotide polymorphisms (SNPs) to reach genome-wide 
significance (p < 5 x 10-8). HLA-DRB1*03:01 showed the most significant association 
with IBM (p = 5.77 x 10-34), followed by HLA-DRB1*01:01 (p = 1.57 x 10-16), and HLA-
DRB1*13:01 (p = 3.28 x 10-8). This finding is consistent with prior HLA-association 
studies identifying an association of IBM with the 8.1 ancestral MHC haplotype (8.1 AH) 
(Garlepp et al. 1994; Badrising et al. 2004; Mastaglia 2009; Needham, James, et al. 
2008). Contrary to previous results that HLA-DRB4 is protective and ameliorates the risk 
effect of HLA-DRB1*03:01 (Rojana-udomsart et al. 2012), no HLA alleles were found to 
modify disease onset or severity of IBM in this study. Furthermore, in agreement with a 
study performed in an Australian cohort, there was no distinct HLA association with anti-
cytosolic 5’-nucleotidase 1A (anti-NT5C1A) positivity (Rothwell et al. 2017; Limaye et al. 
2016).  
 
To investigate whether the risk associated with these HLA-DRB1 alleles could be 
explained by specific amino acid positions shared between alleles, amino acid 




imputation was performed. A tyrosine residue at position 26 was found to be more 
strongly associated with IBM (p < 5.22 x 10-43) than the HLA-DRB1 allele alone, and an 
additional independent effect was seen at position 11 (p < 3.8 x 10-13) for serine. Of note, 
previous studies have associated positions 11 and 26 with other autoimmune diseases 
such as systemic lupus erythematosus (Kim et al. 2014). Both of these residues are 
located within the β-sheet floor of DR β-chain 1 that forms part of the peptide-binding 
groove and may influence peptide binding and predispose individuals to autoimmunity 
(Rothwell et al. 2017). Interestingly, although HLA-DRB1*03:01 is also a significant risk 
factor for Polymyositis (PM) and Dermatomyositis (DM), amino acid position 74 explains 
almost all of the risk within the allele for PM and DM (Rothwell et al. 2016).  
 
NOTCH4, a previously identified risk gene within the HLA locus (Scott et al. 2012), was 
not explicitly examined in this study due to its strong linkage disequilibrium with the 8.1 
AH. Three regions outside of the HLA locus that almost reached the level of genome-
wide significance (p < 2.25 x 10-5) included a known frameshift mutation in CCR5 that 
causes a nonfunctional receptor (Rothwell et al. 2017). CCR5 (C-C Chemokine Receptor 
type 5) is an important regulator of T-cell migration, suggesting a potential role for 
chemokines in the pathogenesis of IBM. A recent case-control study analyzing whole 
exome sequencing data on 30 Finnish IBM patients identified seven SNPs found at >2-
fold higher frequency in IBM, and in addition to the HLA locus, implicated genes that 
regulate sphingolipid transport as potential IBM risk factors (Johari et al. 2017).  Overall, 
these recent studies have confirmed that variants within the HLA locus are risk factors 
for developing IBM 
 
 




Genetic Variants Identified in Pathways Related to Proteostasis 
As mentioned previously, both IBM and HIBM syndromes share degenerative myopathic 
features on biopsy including rimmed vacuoles, ubiquitinated protein aggregates, and 15-
18 nm tubulofilamentous “inclusions” observed with electron microscopy. A known cause 
of this pathology shared with many degenerative diseases is disruption of protein 
homeostasis, or proteostasis, as can be caused by impairment of the proteasome or 
autophagy (reviewed in: Klaips, Jayaraj, and Hartl 2018).  For example, IBMPFD is a 
multisystem degenerative disease caused by autosomal dominant inheritance of 
missense mutations in valosin-containing protein (VCP) (Watts et al. 2004). VCP, also 
called p97 or cdc48, is a highly conserved homohexameric ATPase that functions as a 
“segregase” to remove ubiquitinated proteins from macromolecular complexes, and thus 
plays an important role in proteostasis (Meyer and Weihl 2014).  
 
Intriguingly, rare VCP variants have recently been implicated in IBM as well as multiple 
neurodegenerative diseases including Frontotemporal Dementia (FTD), Parkinson’s 
Disease, Amyotrophic Lateral Sclerosis (ALS), and Charcot-Marie Tooth Disease 
(Johnson et al. 2010; Koppers et al. 2012; Majounie et al. 2012; Spina et al. 2013; 
Gonzalez et al. 2014). Rare mutations in other genes, including HNRPA1, HNRPA2B1, 
and SQSTM1 have also been found to cause similar autosomal dominantly inherited 
degenerative diseases affecting muscle, bone, and brain, and have been termed 
“multisystem proteinopathy”, or MSP (Benatar et al. 2013). As with HIBM, MSP patients 
usually present before age 40 without the typical IBM pattern of weakness, and affected 
muscles in MSP display rimmed vacuoles and protein inclusions but lack inflammation. 
However, recent findings suggest that rare variants in these MSP genes may increase 
the risk for developing IBM.  





Using targeted next generation sequencing, Weihl et. al. screened a cohort of 79 IBM 
patients for variants in 38 genes associated with muscular dystrophies, myopathies, 
ALS, and dementia (Weihl et al. 2015).  This candidate-based approach uncovered an 
increased frequency of rare variants in multiple genes including VCP, SQSTM1, FLNC, 
ZASP, and BAG3 as well as a novel variant in HNRPA2B1.  FLNC, SQSTM1, ZASP, and 
BAG3 are known to be mutated in rare inherited vacuolar myopathies and also play 
integral roles in the autophagy pathway (Ruparelia et al. 2016; Behl 2011; Baixauli, 
López-Otín, and Mittelbrunn 2014). SQSTM1 (Sequestosome 1, also known as p62) is a 
ubiquitin-binding autophagic adaptor that has been shown to label protein inclusions in 
IBM muscle (Nogalska et al. 2009; Dubourg et al. 2011; Ikenaga et al. 2017). The two 
rare variants identified in VCP were previously reported as putative disease-associated 
variants (Majounie et al. 2012; Kimonis et al. 2008; Rohrer et al. 2011), and expression 
of these variants in cell culture causes an accumulation of the autophagosome markers 
p62 and LC3-II, suggestive of a disruption in autophagy (Ju et al. 2009). Similarly, other 
candidate-based whole exome sequencing (WES) approaches have also identified rare 
VCP variants in IBM in addition to SQSTM1 (Gang et al. 2016) and ZASP (Cai et al. 
2012). The majority of these variants are in evolutionarily conserved regions, suggesting 
that they may have functional consequences and increase risk for disease. However, 
given the selection bias inherent in candidate-based approaches, further studies are 
necessary to determine whether these variants significantly alter protein function and 
play a role in IBM pathogenesis.  
 
Rather than starting with genes previously implicated in muscle disease, Guttsches et. 
al. performed an unbiased proteomics approach to identify proteins enriched in rimmed 




vacuoles (RVs) (Guttsches et al. 2017). This method led to the identification of 213 
proteins, 40 of which had been previously described in IBM including VCP and p62, 
validating this approach. Interestingly, proteins involved in protein quality control were 
among the most abundantly overrepresented proteins. To look for novel genetic 
contributors to IBM, WES was used to identify variants in genes encoding proteins found 
in RVs. When comparing the burden of these variants to an ALS cohort, only variants in 
the FYCO1 gene were statistically enriched in IBM patients (11.3% vs. 2.6% in controls).  
FYCO1 has been implicated in microtubule transport of autophagosomes, consistent 
with a role for autophagy impairment in the pathogenesis of IBM (Pankiv et al. 2010).     
 
Large Deletions in Mitochondrial DNA and Related Genetic Variants  
Using real-time PCR, COX-deficient fibers from IBM patients were shown to have higher 
mitochondrial DNA (mtDNA) deletion loads when compared to COX-normal fibers 
(Lindgren et al. 2015). In addition, it has been reported that the amount of mtDNA is 
reduced in IBM muscle in comparison to controls (Catalan-Garcia et al. 2016). 
Interestingly, the fraction of COX-deficient fibers correlated with the amount of infiltrating 
T lymphocytes, suggesting an interaction between the mitochondrial defect and the 
autoimmune component of IBM (Rygiel et al. 2015).      
 
Another mitochondrial protein that has been investigated in IBM is the Translocase of 
Outer Mitochondrial Membrane 40 (TOMM40).  TOMM40 lies adjacent to apolipoprotein 
E (ApoE) in the genome, and thus ApoE and TOMM40 alleles are co-inherited. Prior 
studies have shown that the ApoE and TOMM40 genotype combination can be used as 
a predictor of age-dependent risk in Alzheimer’s Disease (AD) (Roses et al. 2013). 
Given reported β-amyloid deposition in both IBM and AD, Mastaglia et al investigated 




ApoE and TOMM40 polymorphisms in IBM (Mastaglia et al. 2013). In a study of 90 
Caucasian patients, they found that carriers of APOE ε3 who also contained the very 
long (VL) poly-T repeat allele of TOMM40 had a reduced risk of developing IBM as well 
as a later age of onset. Recently, Gang et. al. investigated this further in a larger cohort 
of 158 IBM patients obtained through the International IBM Genetics Consortium (Gang, 
Bettencourt, Machado, et al. 2015). In contrast to the previous study, they did not find an 
association between any particular APOE-TOMM40 genotype and the risk of developing 
IBM, but did find that individuals carrying the VL TOMM40 allele had a later age of onset 
(Gang, Bettencourt, Machado, et al. 2015). Since both studies found that the TOMM40 
VL allele delays IBM disease onset, these findings suggest that further investigation into 
how the VL allele alters TOMM40 and mitochondrial function may shed insight into IBM 
pathogenesis.    
 
Conclusion 
New high-throughput sequencing methods have revolutionized genetic analyses of 
complex diseases, allowing for identification of genetic variants that are associated with 
an increased risk of developing IBM. Recent studies have confirmed and refined the 
major role the HLA locus plays in IBM susceptibility, strongly implicating autoimmunity in 
disease pathogenesis.  In addition, multiple studies have identified rare variants within 
genes known to regulate protein quality control including autophagy, suggesting that 
one’s ability to prevent protein aggregate formation may partially underlie disease risk. 
While intriguing, the rare nature of IBM and the presence of most of these variants at low 
levels in the population make the significance of these findings unclear. However, the 
identification of both immune and proteostasis-related genes in disease susceptibility of 
IBM further implicates both processes in IBM pathogenesis. 




1.4 Current Treatments and Ongoing Clinical Trials 
Regrettably, there are no clinically effective treatments that have been shown to improve 
muscle weakness or halt its progression for IBM patients. The standard of care for IBM 
patients includes nonpharmacological management such as physical and occupational 
therapy, education on fall prevention, and the use of medical devices to improve mobility 
such as braces for foot drop and wheelchairs. Interventions to improve dysphagia in IBM 
patients are also common as dysphagia is associated with increased mortality and 
morbidity due to malnutrition, dehydration, and aspiration pneumonia (Oh et al. 2007; 
Mohannak et al. 2019). There are both non-invasive (e.g. lingual strengthening 
programs) and invasive approaches (e.g. balloon dilation, botulinum toxin injection, and 
cricopharyngeal myotomy) for treating dysphagia. These invasive approaches have 
been found to be more effective, and in one study, approximately 60% of patients with 
dysphagia benefitted at least temporarily from undergoing cricopharyngeal myotomy 
(Mohannak et al. 2019).  
 
Exercise in IBM 
Although previously it had been thought that exercise did not significantly alter the 
natural history of IBM, several studies suggest beneficial effects of exercise in IBM 
patients (Spector et al. 1997; Arnardottir et al. 2003; Johnson et al. 2009; Alexanderson 
and Lundberg 2012; Alexanderson 2018). A variety of exercise paradigms have been 
tested in small IBM cohorts, including home exercise programs, resistance strength 
training, and blood-flow restriction training. Importantly, several of these studies 
assessed the effect exercise had on the patient’s immune system and endomysial 
inflammation. Serum CK levels were unaffected by exercise and in studies where 




participants underwent repeated muscle biopsies, changes in the number of 
degenerating fibers or inflammatory cells were not observed (Spector et al. 1997; 
Johnson et al. 2009; Arnardottir et al. 2003). IBM patients undergoing blood-flow 
restriction training did show increased endomysial infiltration of CD3-CD8+ expressing 
natural killer cells, but populations of T cells and macrophages were unchanged (Jensen 
et al. 2019). The main conclusions from these studies were that exercise is well tolerated 
by IBM patients and the exercise arms frequently showed modest improvements in 
aerobic capacity, or improved strength from baseline (Spector et al. 1997; Johnson et al. 
2009). These studies are encouraging, but large, randomized trials examining the 
potential benefits of exercise for IBM patients are still needed. 
 
Clinical Trials 
A modest number of clinical trials—both open-label and blinded placebo-controlled 
trials—have been carried out with IBM patients to test potential pharmaceutical therapies 
targeting immune modulation, the myostatin pathway, or proteostasis (reviewed in: 
Greenberg 2019; Glaubitz, Zeng, and Schmidt 2020). Broad lymphocytic depletion 
treatment strategies tested in IBM patients include antithymocyte globulin (ATG), 
methotrexate, intravenous or subcutaneous immunoglobulin, and alemtuzumab. Most of 
these treatments have shown minimal or no treatment efficacy (Glaubitz, Zeng, and 
Schmidt 2020). For instance, a double-blinded, placebo-controlled study with 
methotrexate showed no difference in progression and muscle strength over 48 weeks, 
although a pilot trial of alemtuzumab in 13 IBM patients suggested reduced progression 
of weakness, and post-treatment biopsies showed reduced endomysial lymphocytes 
(Badrising et al. 2002; Dalakas et al. 2009). It is also worth noting studies have found 
that intravenous immunoglobulin (IVIG) may be beneficial for patients with dysphagia 




(Dalakas et al. 1997; Dobloug et al. 2012). 
 
As therapies targeting inflammatory pathways have only been moderately efficacious at 
best, researchers have been exploring a number of other treatment avenues. A small 
study showed that the myostatin inhibitor Bimagrumab could improve skeletal muscle 
mass in 14 IBM patients (Amato et al. 2014). This was followed by a large randomized, 
placebo-controlled trial of Bimagrumab in 240 patients using a 6-minute walk test as the 
primary outcome, which was not significantly changed compared to the placebo-
controlled group (Hanna et al. 2019). 
 
Recently, a study evaluated the therapeutic potential of targeting protein aggregation in 
IBM with Arimoclomol (Ahmed et al. 2016). Arimoclomol is a small molecule thought to 
upregulate chaperone expression in stressed cells, thereby reducing the formation of 
protein aggregates (Kieran et al. 2004; Douglas and Cyr 2010). In cultured myoblasts 
and mice expressing mutant VCP protein, Arimoclomol improved IBM-like pathology, 
and in a small proof-of-concept clinical study, there was a trend toward reduced decline 
in muscle strength and physical function in IBM patients taking Arimoclomol compared to 
placebo (Ahmed et al. 2016) . A multisite phase II clinical trial (NCT02753530) began in 
2018 to evaluate the efficacy of this drug in IBM and the study is predicted to conclude in 
December of 2021.  
 
Recent success in clinical trials of gene therapy in Spinal Muscular Atrophy (SMA), an 
inherited motor neuron disease (Mendell, Al-Zaidy, et al. 2017; Finkel et al. 2017; 
Ramdas and Servais 2020), in addition to excitement around using genome editing 
technologies such as CRISPR for treating muscle diseases (Bengtsson et al. 2017; 




Amoasii et al. 2018; Jin et al. 2019), has led to the consideration of gene therapy for 
IBM.  Since muscle atrophy is a major part of IBM pathology, researchers have analyzed 
the myostatin signaling pathway in IBM muscle. Myostatin is a tumor growth factor beta 
(TGF-β) family member that has a well-defined role as a negative regulator of muscle 
mass, making it a promising therapeutic target for muscle wasting disorders (Elkina et al. 
2011). In particular, gene therapy using follistatin, a natural inhibitor of the myostatin 
receptor, has been reported to be safe and causes muscle hypertrophy in mice and 
primates (Kota et al. 2009). Since the myostatin signaling pathway was reported to be 
upregulated in IBM (Amato et al. 2014), follistatin gene therapy has been tested to 
determine if it improves muscle strength and function in IBM.   
  
In a recent phase 1/2a clinical trial, adeno-associated viral (AAV) delivery of follistatin 
isoform 344 (FS344) via intramuscular quadriceps injection was reported to modestly 
improve the distance traveled for a 6 minute walk test (6MWT) in a small cohort of 
Becker muscular dystrophy (BMD) patients (Mendell et al. 2015). Promising histological 
changes were also observed including reduced endomysial fibrosis, fewer centralized 
nuclei, and normalization of fiber size. In a ‘proof-of-principle’ trial, 6 male IBM patients 
received bilateral intramuscular quadriceps injections of AAV1 vectors carrying FS344 
(Mendell, Sahenk, et al. 2017). One noteworthy change from the BMD study is that the 
IBM study included an exercise regimen for each participant as it had been 
demonstrated that exercise increased plasma levels of follistatin (Hansen et al. 2011). 
This study observed an improvement in the distance traveled for a 6MWT, and all post-
treatment biopsies showed increased number of muscle fibers (Mendell, Sahenk, et al. 
2017). However, significant concerns have been raised in regards to the design of this 
trial and the authors’ claim of efficacy (Greenberg 2017). Most importantly, the lack of a 




control group makes it difficult to determine how much of the improvement was a result 
of exercise and/or placebo effect.  
1.5 Laboratory Models of Inclusion Body Myositis 
To date, the xenograft model described below in Chapter 5 is the only comprehensive 
animal model of IBM. A plethora of laboratory models have been developed for various 
forms of HIBM, such as transgenic mutant VCP mouse models (Weihl et al. 2007; 
Custer et al. 2010), a knock-in mutant VCP model (Nalbandian et al. 2013), GNE 
myopathy models (reviewed in:Pogoryelova et al. 2018), and various Drosophila models 
(Ritson et al. 2010; Chang et al. 2011; Wang et al. 2012; Li et al. 2016). However, to 
reiterate, while HIBMs share some pathological features with IBM, they are clinically 
distinct from sporadic IBM in that they lack inflammation (which is prominent in sporadic 
IBM), have a much earlier age of onset, and have a different pattern of muscle 
involvement. 
 
Outside of the HIBM models, several labs have developed animal models that 
recapitulate specific characteristics of IBM (reviewed in: Afzali et al. 2017). The majority 
of these models involve using either pharmacologic or transgenic means to drive β-
amyloid (Aβ) aggregation in skeletal muscle. One group performed intraperitoneal 
injections of Wistar rats with chloroquine diphosphate: an anti-malaria drug that can 
cause a vacuolar myopathy (Ikezoe et al. 2009). Prior to rimmed vacuole formation at 7 
weeks post-treatment, they observed increased levels of LC3-II—indicating increased 
autophagy—and Aβ in skeletal muscle followed by an elevated unfolded protein 
response (UPR). The authors hypothesized that Aβ accumulation may be driving ER 




stress in their model eventually leading to degeneration of myofibers (Ikezoe et al. 
2009). Interestingly, when this chloroquine rat model was challenged with resistance 
exercise—rats climbed a ladder with weight attached to their tails 9 weeks after starting 
treatment—it was found that exercise reduced Aβ accumulation, which rescued muscle 
atrophy and increased expression of key regulators of mitochondrial biogenesis (Koo, 
Kang, and Cho 2019). Another group generated a transgenic animal model in which 
human wild-type (WT) β-amyloid precursor protein (βAPP) was expressed in fast-twitch 
(type II) skeletal muscle (Moussa et al. 2006). Hemizygous transgenic mice showed 
increased levels of βAPP and Aβ in skeletal muscle fibers, and they became significantly 
weaker with age in comparison to nontransgenic littermates. In addition, dissociated 
muscle fibers from transgenic mice exhibited a 2-fold increase in resting calcium and 
membrane depolarization compared with nontransgenic littermates (Moussa et al. 2006). 
These latter characteristics may explain the persistent muscle weakness in IBM, 
however, the potential contribution of βA and βAPP in the pathogenesis of IBM remains 
controversial (Greenberg 2009; Fergusson 2009). 
 
A striking feature of IBM biopsies is the dramatic sarcoplasmic and sarcolemmal 
upregulation of MHC-I, and several groups have developed models to explore this 
characteristic. First, a conditional mouse model was developed where overexpression of 
MHC-I (mouse H-2Kb) was driven by a muscle-specific promoter repressible with 
doxycycline (Nagaraju et al. 2000). After doxycycline was removed at 4 weeks, these 
transgenic mice showed specific upregulation of MHC-I, impaired locomotor activity, and 
increased serum levels of CK and glutamic-oxaloacetic transaminase, indicating ongoing 
muscle damage compared to littermates. By 3.5 months, skeletal muscles showed 
myopathic features including internalized nuclei and degenerating fibers as well as 




macrophage infiltration. Readministration of doxycycline for 5 months after 4 months of 
transgene expression was unable to rescue these phenotypes, and expression of MHC-I 
remained elevated, indicating the persistent, uncontrollable nature of this inflammatory 
response once initiated (Nagaraju et al. 2000). Another group used this model to assess 
the impact of this MHC-I overexpression in young muscle tissue and reported a more 
severe phenotype when doxycycline was removed immediately after weaning (Li et al. 
2009). Gene expression analysis of these mice revealed up-regulation of genes involved 
in protein transportation, folding, processing, and glycosylation such as Hsp40 
chaperones and derlin proteins (Li et al. 2009). In addition, several significantly over-
expressed genes were part of the UPR, such as Armet, a clear parallel to the 
chloroquine rat model discussed above. The UPR is activated to handle misfolded or 
overexpressed proteins and is characterized by the expression of ER chaperones, 
reduced protein synthesis, and enhanced degradation of misfolded proteins by the 
ubiquitin-proteasome system and ER-associated degradation. Interestingly, when MHC-I 
is overexpressed in the skeletal muscle of immunodeficient, alymphoid mice, proteomic 
analysis also shows upregulation of the UPR indicating this process is intrinsic to 
myofibers and can occur independently from involvement with the adaptive immune 
system (Freret et al. 2013). It is important to note that MHC-I staining is also commonly 
seen in muscle biopsies from patients diagnosed with non-inflammatory myopathies and 
neurogenic disorders, whereas MHC-II staining is more specific to inflammatory 
myopathies (Rodriguez Cruz et al. 2014). Therefore, it would be informative to explore 
the effect of conditionally overexpressing MHC-II in skeletal muscle.   
  
To explore the involvement of anti-NT5C1A in IBM pathology, a passive in-vivo 
immunization model has been developed by injecting mice with immunoglobulin (IgG) 




samples from IBM patients with and without NT5C1A antibodies. Mice injected with anti-
NT5C1A positive patient serum showed myopathic features (e.g. fiber size variation), 
p62 aggregates in muscle, and macrophage infiltration (Tawara et al. 2017). As a next 
step, this group has also developed an active immunization mouse model using NT5C1A 
peptides (Chinoy and Lilleker 2019: P131). Of the three different peptide sequences 
injected into mice, autoantibodies recognizing the injected NT5C1A peptides were 
detected in the sera of all the mice (5 per group). Two of the peptide-injected groups 
showed a significant decrease in motor activity, and one group also showed increased 
expression of p62 and LC3-II in muscle lysates as detected via western blot (Chinoy and 
Lilleker 2019: P131). These models show that mice immunized passively or actively to 
develop antibodies to NT5C1A can mimic some pathological features of IBM; however, 
more research is needed to understand the of role anti-NT5C1A in IBM.  
 
While the models described above are useful tools to elucidate the basic biology 
underlying discrete elements of IBM pathology, none of them could be described as a 
comprehensive laboratory model showing the full spectrum of pathological features. 
Increasingly, xenograft models of disease —where human tissue is transplanted in 
immunocompromised mice—have proven to be valuable tools for rare or sporadic 
diseases that often lack laboratory models and they have propelled therapeutic 
development, especially in oncology. 




Chapter 2: Using Xenografts to Study 
Human Disease 
2.1 The Use of Patient Derived Xenografts in Cancer 
The first immortal human cell line was created in Dr. George Gey’s laboratory by the 
technician Mary Kubicek who successfully cultured cells from a sample of Henrietta 
Lacks’ cervical cancer at Johns Hopkins Hospital (Scherer, Syverton, and Gey 1953). 
This HeLa cell line has had an immeasurable impact on human medicine, and it is only 
natural that in vitro cell culture models dominated cancer research for decades. In 2012 
the Cancer Cell Line Encyclopedia (CCLE) compiled gene expression, chromosomal 
copy number, and parallel sequencing data from 947 human cancer cell lines to aid in 
predictions of drug sensitivity (Barretina et al. 2012). In a recent amendment, the number 
of lines rose to 1,072 and the characterization of the cell lines expanded to include data 
on RNA splicing, DNA methylation, and histone H3 modification among other 
characteristics (Barretina et al. 2019). This vast array of cancer cell lines have been 
used for both in vitro and in vivo studies, in particular, the most frequently used models 
for preclinical therapeutic testing have historically been xenograft models generated by 
injecting these cells into immunodeficient mice (Jung, Seol, and Chang 2018). While 
such models are easy to generate, they have a number of limitations. Most importantly 
these models do not recapitulate the heterogenous population of cells found within the 
tumor microenvironment, and they typically fail to predict drug efficacy in patients. To 
overcome these shortcomings, researchers have turned to patient-derived tumor 
xenografts (PDX).  
 




The first successful PDX model was developed by subcutaneously transplanting tissue 
from a metastatic adenocarcinoma into athymic, nude mice (Rygaard and Povlsen 
1969). Although the xenografts regressed in control mice, they showed rapid growth in 
nude mice, and 40 days after transplantation the tumor mass more than doubled. More 
than five decades have passed since this initial study, and PDX models have been 
developed for the majority of solid tumors including urothelial and renal cell carcinomas, 
prostate cancer, and glioblastomas (Namekawa et al. 2019; Lee et al. 2019; Tracey et 
al. 2020). One clear issue that can arise when using PDX models is tissue availability as 
not all universities or laboratories have ready access to patient samples. However, 
numerous serially transplantable PDX models have been established to address this 
issue of accessibility (Dobrolecki et al. 2016; Navone et al. 2018). To date, the Jackson 
Laboratory’s Mouse Models of Human Cancer Database (MMHCDB), a compendium of 
mouse models of human cancer, lists over 400 patient-derived xenograft (PDX) models 
(Krupke et al. 2017). 
 
It is clear that PDXs models have been successfully utilized to develop laboratory 
models and treatments for common cancers, including multiple myeloma, as well as 
personalized therapies for individual patients (Kim et al. 2005; Rubio-Viqueira and 
Hidalgo 2009; Sako et al. 2010; Roberts et al. 2014; Izumchenko et al. 2017). Although 
some characteristic hallmarks of cancer—uncontrollable proliferation and tissue 
invasion—undoubtably predispose the success of PDX models in oncology, researchers 
have expanded the use of xenografts to successfully study other diseases including 
disorders of skeletal muscle (Fouad and Aanei 2017). 




2.2 Using Xenografts to Study Muscle Disease 
The most frequently used method for producing skeletal muscle xenografts is the 
injection of myogenic cells (e.g. satellite cells, iPSCs, or myoblasts) into immunodeficient 
mice following preinjury of the injection site via cardiotoxin, cryodamage, or irradiation to 
create a favorable niche for engraftment (reviewed in: Mueller and Bloch 2019). This 
process creates a chimeric muscle within the host mouse containing both murine and 
human myofibers. Originally nude or SCID mice were preferred hosts as these mice lack 
T cells or all lymphocytes, respectively, which make them permissive for xenograft 
studies. However, improved immunocompromised mouse models have been developed 
in recent years. In particular, NOD-Rag1 (null) strains carrying the IL2rγ (null) mutation, 
such as NSG and NRG mice, more readily support engraftment of human tissue (Silva-
Barbosa et al. 2005; Maykel et al. 2014).  
 
Three major obstacles to successful engraftment of myogenic precursors are early 
progenitor cell death, limited cell proliferation, and poor migration within engrafted 
muscle (Riederer et al. 2012). In addition, the injection of a homogenous population of 
cells does not fully recapitulate the heterogenous population of cells found within the 
skeletal muscle niche. For instance, fibro-adipogeneic progenitors (FAPs) massively 
proliferate in skeletal muscle following muscle injury and their intercellular interactions 
drive satellite cell activation and promote efficient regeneration (Farup et al. 2015; 
Malecova et al. 2018; Biferali et al. 2019). In a mouse model of limb girdle muscular 
dystrophy 2B, progressive accumulation of Annexin A2—a calcium-dependent 
phospholipid-binding protein involved in exocytosis—in the myofiber matrix causes FAPs 
to preferentially differentiate into adipocytes driving fatty replacement of myofibers 




(Hogarth et al. 2019). These data implicate FAPs in the adipogeneic replacement of 
myofibers commonly seen in muscle diseases, including IBM, and showing the 
importance of cells beyond myogenic precursors in skeletal muscle regeneration. 
 
Another approach to generate human skeletal muscle xenografts is to transplant whole 
muscle grafts into immunodeficient host mice. The first proof-of-principal study that 
unintentionally tested this approach involved the transplantation of muscle from 
dystrophic mdx mice to control mice sharing the same genetic background (Morgan, 
Coulton, and Partridge 1989). While the goal of this study was to demonstrate that the 
mdx mutation caused a muscle intrinsic primary myopathy, it also revealed that whole 
muscle grafts could regenerate in host mice and maintain their original genetic profile 
(Watt et al. 1987; Morgan, Coulton, and Partridge 1989).  
 
More recently, whole muscle xenografts have been used to develop a model of 
fascioscapulohumeral muscular dystrophy (FSHD) (Zhang et al. 2014). In this model, 
human muscle biopsy specimens are transplanted into the hindlimbs of immunodeficient 
NRG mice to form xenografts. The transplanted human myofibers die, but human 
satellite cells present in the xenograft subsequently expand and differentiate into new 
human myofibers which repopulate the engrafted human basal lamina. Therefore, the 
regenerated myofibers in these xenografts are entirely human and are spontaneously 
revascularized and innervated by the mouse host. Importantly, FSHD patient muscle 
tissue transplanted into mice recapitulates key features of the human disease, namely 
expression of the DUX4 transcription factor (Zhang et al. 2014). FSHD is caused by 
overexpression of DUX4, which is epigenetically silenced in normal muscle tissue 
(Gabellini, Green, and Tupler 2002; Lemmers et al. 2010). In the FSHD xenograft model, 




treatment with a DUX4-specific morpholino has been shown to successfully repress 
DUX4 expression and function and may be a potential therapeutic option for FSHD 
patients (Chen et al. 2016).  
 
These studies demonstrate that human skeletal muscle xenografts are a promising 
approach to model muscle disease and test potential therapies in mice. In a novel 
application of this methodology, this study demonstrates that human skeletal muscle 
xenografts can be used to model acquired, inflammatory muscle diseases, such as IBM.  








This is adapted from Britson, K. A., Black, A. D., Wagner, K. R., Lloyd, T. E. Performing 
Human Skeletal Muscle Xenografts in Immunodeficient Mice. J. Vis. Exp. (151), e59966, 
doi:10.3791/59966 (2019) (Britson et al. 2019). Reprinted in this dissertation with 
permission from the Journal of Visual Experiments, pursuant to their Author License 
Agreement. 
3.1 Introduction 
It has been reported that only 13.8% of all drug development programs undergoing 
clinical trials are successful and lead to approved therapies (Wong, Siah, and Lo 2019). 
While this success rate is higher than the 10.4% previously reported (Hay et al. 2014), 
there is still significant room for improvement. One approach to increase the success 
rate of clinical trials is to improve laboratory models used in preclinical research. The 
Food and Drug Administration (FDA) requires animal studies to show treatment efficacy 
and assess toxicity prior to Phase 1 clinical trials. However, there is often limited 
concordance in treatment outcomes between animal studies and clinical trials (Perel et 
al. 2007). In addition, the need for preclinical animal studies can be an insurmountable 
barrier for therapeutic development in diseases that lack an accepted animal model, 
which is often the case for rare or sporadic diseases. 
 




One way to model human disease is by transplanting human tissue into immunodeficient 
mice to generate xenografts. There are three key advantages to xenograft models: First, 
they can recapitulate the complex genetic and epigenetic abnormalities that exist in 
human disease that may never be reproducible in other animal models. Second, 
xenografts can be used to model rare or sporadic diseases if patient samples are 
available. Third, xenografts model the disease within a complete in vivo system. For 
these reasons, we hypothesize that treatment efficacy results in xenograft models are 
more likely to translate to trials in patients. Here, we describe in detail the surgical 
method for creating human skeletal muscle xenografts in immunodeficient mice. 
3.2 Protocol 
All use of research specimens from human subjects was approved by the Johns Hopkins 
Institutional Review Board (IRB) to protect the rights and welfare of the participants. All 
animal experiments were approved by the Johns Hopkins University Institutional Animal 
Care and Use Committee (IACUC) in accordance with the National Institutes of Health 
(NIH) Guide for the Care and Use of Laboratory Animals. 8 to 12-week-old male NOD-
Rag1null IL2rγnull (NRG) host mice (Jackson Laboratory, 007799) are used to carry out 
xenograft experiments. These mice are housed in ventilated racks and are given HEPA-
filtered, tempered, and humidified air as well as reverse osmosis filtered 
hyperchlorinated water. Mice are provided water and an irradiated antibiotic diet (Envigo, 
TD.06596) ad libitum, and the facility provides 14 hours of light to 10 hours of dark as 
controlled by central timer. 
 
 




1. Equipment preparation  
1.1. Acquire NOD-Rag1null IL2rγnull (NRG) mice, 8-12 weeks of age. 
1.2. Autoclave surgical equipment: scissors, forceps, needle holder, surgical stapler 
(Table 3.1), wound clips, surgical wipes (Table 3.1), and beaker. 
1.3. Prepare 50 mL of muscle media (20% fetal bovine serum, 2% chick embryo extract, 
1% antibiotic/antimycotic in Hams F10 Medium). Keep all chemicals/drugs/solutions 
used for surgery at room temperature unless stated differently in the protocol. 
1.4. Prepare a 1 mL syringe with a 26-gauge needle that is 3/8 inches long containing 2 
mg/mL analgesic (Table 3.1), and place on ice. The analgesic can be diluted to the 
proper concentration using sterile phosphate buffered saline (PBS). 
 
2. Surgical preparation  
2.1. Obtain a human muscle biopsy under an IRB-approved protocol from patients 
whose muscles display strength > 4-/5 on the MRC (Medical Research Council) scale 
(MRC 1976). Place the research specimen in a 100 mm x 15 mm Petri dish containing 
muscle media.  
NOTE: The MRC scale is used in clinical practice as an assessment of muscle 
strength with 0 showing no contraction, 5 showing normal power, and 4 (4- to 4+) 
showing movement against resistance (MRC 1976). We have found that muscles 
with mild to moderate weakness (MRC > 4-/5) typically show disease pathology 
but are not extensively replaced by fatty tissue or fibrosis, both of which impede 
xenograft regeneration. In the case of autopsy tissue where a recent MRC score 
is not available, muscle quality can be accessed via gross observation. Muscle 
biopsies that are pale pink in appearance or have large areas of fatty tissue are 
not likely to xenograft successfully. 




2.2. Remove any remaining fascia or fatty tissue from the specimen with surgical 
scissors using a stereo microscope and light source to assist visualization. 
2.3. Dissect the muscle biopsy into approximately 7 mm x 3 mm x 3 mm pieces with 
surgical scissors using the stereo microscope and a light source. Ensure fibers are 
arranged longitudinally within the specimen.  
2.4. Place the Petri dish containing dissected muscle on ice. On average, the xenografts 
are kept in media for 4 hours while surgeries are being performed. However, biopsies 
have been stored in media for 24 hours prior to xenografting, and this delay did not 
appear to negatively impact transplantation or regeneration.  
2.5. Place synthetic, non-absorbable sutures (Table 3.1) in a 100 mm x 15 mm Petri 
dish containing 70% ethanol. 
2.6. Set up a dual procedure anesthesia circuit: arrange the Mapleson E breathing circuit 
on the stereo microscope and place the induction chamber in a biosafety cabinet. 
2.7. Obtain the weight of the NRG mouse by placing in an autoclaved beaker on a scale, 
and transfer to the induction chamber. Induce anesthesia under 3% isoflurane. Once the 
appropriate anesthetic depth is achieved—as assessed by observation of respiratory 
rate, muscle relaxation, and lack of voluntary movement—reduce the vaporizer setting to 
1.5% for the remainder of the surgery.  
2.8. Transfer the mouse from the induction chamber to the Mapleson E breathing circuit 
and apply ophthalmic ointment to eyes.  
2.9. Remove hair overlying the tibialis anterior (TA) from ankle to knee with a trimmer, 
followed by a 1-minute treatment with hair removal lotion (Table 3.1) (Figure 3.1).  
2.10. Disinfect the surgical site by swabbing the leg with povidone-iodine solution. Then 
wash away the remaining povidone-iodine with 70% ethanol. 
2.11. Inject the mouse subcutaneously with analgesic (Table 3.1) at a dose of 5 mg/kg. 





3. Xenograft surgery  
3.1. Tape down the leg and make a straight incision over the tibialis anterior (TA) muscle 
with scissors and iris forceps originating at the distal tendons and terminating below the 
knee (Figure 3.1A, B).  
3.2. Separate skin from muscle using blunt dissection with surgical scissors. 
3.3. Cut through the epimysium of the TA muscle with scissors starting at the tendon and 
ending at the knee.  
NOTE: This is a very superficial cut (less than 0.5 mm; Figure 3.1B, black 
dashed line), and the underlying TA should not be damaged in the process as 
this would make removal more challenging. When performed correctly, the 
muscle fibers will visibly relax.  
3.4. Cut the distal tendon of the TA with scissors, grab the tendon with iris forceps, and 
pull the TA up toward the knee (Figure 3.1C).  
3.5. Cut the distal tendon of the extensor digitorum longus (EDL) with scissors and pull 
the EDL up toward the knee (Figure 3.1D). Once the proximal tendon of the peroneus 
longus (PL) muscle is visible, remove the EDL with scissors (Figure 3.1D, green dashed 
line). 
3.6. Remove the TA with scissors (Figure 3.1D, blue dashed line) and use a surgical 




3.7. Thread a suture through proximal peroneus longus (PL) tendon and trim, leaving 
approximately 1.5 inch of thread on either side of the tendon (Figure 3.1F). 




3.8. Perform the first half of a two-hand surgical square knot, but do not tighten: this will 
form a circle. Place a xenograft in this circle and tighten the loop to secure the xenograft. 
Complete the other half of the square knot (Figure 3.1G, H). This will suture the 
xenograft to the proximal tendon of the PL. 
NOTE: The medial tarsal artery and vein can lie close to or on top of the distal 
tendon of the PL. Do not place sutures through or around these vessels. It is 
easy to tell if a suture has been improperly placed as vessels will blanch or 
bleed. If this occurs, remove the suture and place in a different location. 
3.9. Thread suture through distal PL tendon and repeat the square knot technique from 
step 3.8 to tie the xenograft to the distal tendon (Figure 3.1H, I).  
3.10. Pull skin over xenografted muscle, seal with surgical glue, and place 2-3 surgical 
staples over the incision (Figure 3.1J). 
3.11. Place mouse in a clean cage on a heated pad to recover. Monitor mouse until fully 
conscious and periodically over the next few days for signs of local systemic infection 
and to ensure the surgical site is not reopened.  
 
4. Xenograft collection 
NOTE: Xenografts are typically collected between 4 to 6 months post-surgery. 
However, collections have been performed up to 12 months post-surgery.  
4.1. Place a covered beaker containing 200 mL of 2-methylbutane in a box containing 
dry ice for a minimum of 30 minutes before xenograft collection.  
4.2. Induce anesthesia under 3% isoflurane in induction chamber. Once the appropriate 
anesthetic depth is achieved, reduce the vaporizer setting to 1.5% for the remainder of 
the surgery.  




4.3. Transfer the mouse from the induction chamber to the Mapleson E breathing circuit 
arranged on a stereo microscope. 
4.4. Remove hair overlying the tibialis anterior from ankle to knee with a trimmer and hair 
removal lotion. The sutures holding the xenograft in place can be seen through the skin 
(Figure 3.2A). 
4.5. Tape down the leg and use scissors and iris forceps to open skin over the xenograft 
until both sutures are visible (Figure 3.2B). Skin overlying the xenograft can be removed 
as shown to make removal of the xenograft easier (Figure 3.2C). 
4.6. Use a scalpel to cut between the PL muscle and the gastrocnemius muscle (Figure 
3.2D, E, incision along epimysium labeled with arrow). The PL will be removed with the 
xenograft.  
4.7 Use a scalpel to cut between the xenograft and the tibia (Figure 3.2E, arrow denotes 
initial site and direction of incision).  
4.8. Cut below the distal suture and through the distal tendon of the PL (Figure 3.2F, the 
arrow indicates where the tendons are cut).  
4.9. Remove the xenograft and PL by grabbing the suture with iris forceps and deflecting 
it toward the knee while using scissors to cut it away from the underlying muscle (Figure 
3.2J). 
4.10. Cut above the proximal suture with scissors to remove the xenograft and PL 
(Figure 3.2J, cut along dotted line). 
4.11. Place the specimen on a small piece of cardboard or plastic, and pin as close to 
the sutures as possible. While pinning the specimen, gently stretch the muscle to ensure 
that the fiber orientation is maintained during the snap freezing process. After the pins 
are securely in place, slide the muscle up the pins so it rests just above the cardboard. 




NOTE: Alternatively, one end of the xenograft can be mounted in tragacanth on a 
cork, or it can be submerged entirely in optimal cutting temperature (O.C.T.) 
compound in a cryomold. With care, muscle conformation can be retained with 
both methods.  
4.12. Snap freeze the xenograft in pre-cooled 2-methylbutane.  
4.13. Store xenograft at -80 °C.  
4.14. Immediately following xenograft collection, euthanize mice in accordance with 
American Veterinary Medical Association guidelines:  
4.14.1. Place mice in a sealed chamber with an appropriate waste gas 
scavenging system. Use isoflurane at a concentration of 3-4% to induce 
anesthesia.  
4.14.2. Once the appropriate anesthetic depth is achieved—as assessed by 
observation of respiratory rate, muscle relaxation, and lack of voluntary 
movement—increase the vaporizer setting to 5% to induce death. Leave the 
mice in the chamber for an additional 2 minutes after breathing has ceased. 
Death is verified by observing that the mice fail to recover within 10 minutes after 
overdose of isoflurane.  
4.14.3. Finally, perform cervical dislocation on the mice. 
NOTE: In the case of bilaterally xenografted mice, the contralateral xenograft can be 
saved for a later collection. To perform a survival collection, open the skin overlying the 
xenograft with a single straight cut with surgical scissors, and remove the xenograft as 
described in steps 4.6 to 4.10. Then close the skin over the empty tibial compartment 
using surgical glue and staples. Treat the mouse with analgesic as described in step 
2.11 and place the mouse in clean cage on heated pad to recover. Monitor the mouse 




until fully conscious and periodically over the next few days for signs of local systemic 
























































Table 3.1 Materials for Xenograft Surgery. A summary of all equipment and reagents 











































Figure 3.1 A) Hair is removed from surgical site. B) An incision is made over the tibialis anterior 
(TA). The distal tendons of the TA and extensor digitorum longus (EDL) are marked with arrows. 
The black dashed line indicates where the epimysium will be cut in step 3.3. C) The distal tendon 
of the TA is cut and the muscle is pulled up to the knee. D) The tendon of the EDL is cut and the 
EDL is pulled up to the knee. This exposes the proximal tendon of the peroneus longus (PL) marked 
with an arrow. Dashed lines indicate where to cut with scissors to remove the EDL (green) and PL 
(blue). E) The EDL and TA are removed. F) A suture is placed through the proximal tendon of the 
PL. G) The xenograft is placed in the empty tibial compartment and sutured to the proximal PL 
tendon using a two-hand surgical square knot. H) A suture is placed through the distal tendon of 
the PL, marked with an arrow, and another two-hand surgical square knot is used to suture the 
xenograft to the distal tendon. I) The xenograft is fully transplanted and sutured to the PL. J) The 
























Figure 3.2 A) Hair is removed from surgical site. Sutures are visible under skin. B) An incision is 
made over the top of the xenograft. C) The skin overlying the xenograft is removed. D) By pulling 
the gastrocnemius muscle to the side, a faint white line of epimysium separating the peroneus 
longus (PL) muscle and the gastrocnemius becomes visible (shown by the arrow). Use the 
scalpel to cut along this line to separate the PL from the other leg muscles. E) Starting at the 
ankle, a scalpel is used to cut along the tibia and free the xenograft. The arrow shows the 
beginning of the incision along the tibia. F) The right side of the xenograft, and the PL are now 
free from the other muscles in the leg and are ready for removal. The arrow indicates where the 
tendons are cut with surgical scissors to start removing the xenograft and PL. J) After cutting 
below the distal suture, deflect the xenograft toward the knee. The dashed line indicates where to 
cut with surgical scissors to remove the xenograft and PL from the tibial compartment. F) The 
empty tibial compartment with the xenograft and PL successfully removed. 
 





As demonstrated by Yuanfan Zhang et al., this surgical protocol is a straightforward 
method to produce human skeletal muscle xenografts (Zhang et al. 2014). Regenerated 
xenografts become spontaneously innervated and display functional contractility. In 
addition, muscle xenografted from FSHD patients recapitulates changes in gene 
expression observed in FSHD patients (Zhang et al. 2014). 
 
In our experience, approximately 7 out of 8 xenografts performed from control patient 
specimens will show successful muscle engraftment. A successful xenograft shows 
robust regeneration of human myofibers as identified with human specific antibodies 
(Figure 3.3). Positive embryonic myosin staining within a proportion of myofibers 
indicates that the regeneration process is still ongoing. In contrast, poor surgical 
technique or an inadequate specimen may lead to poor regeneration of muscle fibers 
(Figure 3.3). 
 
Xenografts performed from a patient diagnosed with an idiopathic inflammatory 
myopathy (IIM) show moderate numbers of regenerated human myofibers at 4- and 6-
month collections, and embryonic myosin staining persists at 6 months (Figure 3.4A). 
Inflammatory cells are present in the xenograft as shown by H&E staining (Figure 3.4A), 
and have been confirmed with CD3, CD68, and other immunological markers (data not 
shown). Xenografts are stable within the mouse, and up to 12-month collections have 
been performed. Individual myofiber size is comparable between the 4- and 6-month IIM 
xenografts and the original IIM patient biopsy (Figure 3.4B). Rare fibers showing a cross 
sectional area (CSA) greater than 3500 μm2 are observed in xenografts but not in the 




IIM biopsy, indicating that some myofibers in the xenografts can regenerate to a CSA 
comparable in size to healthy myofibers (Figure 3.4B). 
 
 

































Figure 3.3 Xenografts collected 4-months post-surgery showing good or poor regeneration are 
stained with human-specific lamin A/C (1:50) and human-specific spectrin (1:20) and embryonic 
myosin (1:10) (Table 3.1). Regions indicated by the white dashed boxes are shown as higher 


























Figure 3.4 A) Xenografts (outlined with dashed lines) performed from a patient diagnosed with an 
idiopathic inflammatory myopathy (IIM) stained with Hematoxylin and Eosin (H&E), human 
specific Lamin A/C, and human specific spectrin, show myofiber formation within NRG mice at 
both 4- and 6-month time points. Embryonic myosin staining demonstrates that regeneration is 
still ongoing at both time points. Scale bar: 200 µm. B) Histograms depicting cross sectional area 
(CSA) of myofibers from 4- and 6-month xenografts and human biopsies from one patient 
diagnosed with an idiopathic inflammatory myopathy (IIM) and one healthy control patient. 
 





Patient-derived xenografts are an innovative way to model muscle disease and carry out 
preclinical studies. The method described here to create skeletal muscle xenografts is 
rapid, straightforward, and reproducible. Unilateral surgeries can be performed in 15 to 
25 minutes, or bilaterally in 30 to 40 minutes. Bilateral xenografts can provide additional 
experimental flexibility. For instance, researchers can perform localized treatment of one 
xenograft, with the other left as a control. The NRG mice are resistant to surgical site 
infection when housed in a pathogen-free facility; in our experience performing more 
than 300 xenografts, we have never had a mouse acquire a surgical infection. In 
addition, host mice tolerate the removal of the TA and EDL very well. Within an hour 
post-surgery, unilaterally and bilaterally xenografted mice will be active and walking 
around their cage, and even standing up on their hindlimbs. Occasionally we observe 
some foot drop in host mice, but usually only after a period of inactivity, such as if 
recently awoken, and within minutes of waking leg use will be normal. 
  
There are several critical steps in the protocol. First, during removal of the EDL and TA, 
it is very important to not injure the adjacent PL muscle or its tendons. This can be 
avoided by carefully and correctly identifying the placement of all distal tendons after the 
initial incision over the TA is performed. In addition, the proximal tendon of the PL should 
be identified and clearly visible before removal of the EDL (Figure 3.1D). Second, 
sutures must be placed through tendons and tightened fully in a proper two-hand 
surgical square knot. Xenografts regenerate more robustly under tension, and this is 
only obtainable if the xenograft is tethered to the PL tendons and if the sutures do not 
loosen post-operatively. Finally, it is important to not damage or sever any major blood 




vessels supplying the foot. In particular, the medial tarsal artery and vein can lie close to 
or on top of the distal tendon of the PL. Do not place sutures through or around these 
vessels. It is easy to tell if a suture has been improperly placed as vessels will blanch or 
bleed. If this occurs, remove the suture and place in a different location. 
 
This method does have several limitations. It is not amenable to standard functional 
assays used in mouse models of muscle disease, such as grip strength or treadmill 
endurance. However, electrophysiological assessments of xenograft function can still be 
performed. Evoked force measurements can be recorded from collected xenografts, and 
single enzymatically isolated myofibers from xenografts loaded with ratiometric calcium 
dyes and electrically stimulated can be used to study calcium dynamics (Zhang et al. 
2014). Another inherent challenge in this model is that acquiring and working with 
human tissue can be difficult. Not all laboratories will have easy access to fresh muscle 
biopsies, but it has been shown that xenografts performed from autopsy tissue 
approximately 48 hours post-mortem can successfully engraft, and this tissue may be 
easier to obtain for some laboratories (Zhang et al. 2014). It is also challenging to 
manipulate gene expression in human tissue, whereas researchers using standard 
mouse models of disease can readily use the plethora of mouse genetic tools available.  
 
A strength of this xenograft model is that it allows researchers to study human muscle in 
vivo. Tissue culture has been used extensively to study the cell and molecular biology of 
human muscle. Yet, these short-term, ex vivo studies do not always approximate 
functional muscle in vivo. However, one caveat is that it is challenging to determine how 
closely xenograft biology and function approximates human muscle due to the 
contribution of components from the host mouse during the regenerative process. For 




instance, human and mouse neuromuscular junctions (NMJs) are morphologically 
distinct, and there is significant divergence between the synaptic proteome of human 
and mouse NMJs (Jones et al. 2017). As xenografts are innervated by the mouse host, 
this may result in biological changes unique to the human xenografts. 
 
In future studies, this skeletal muscle xenograft method could be used to better 
understand human muscle cell biology and to develop novel models for rare or acquired 
muscle diseases that currently lack animal models. We anticipate that this will have a 
significant beneficial impact on therapeutic development for these diseases. 
 




Chapter 4: Methods 
Human Muscle Biopsy 
All use of research specimens from human subjects was approved by the Johns Hopkins 
Institutional Review Board (IRB) to protect the rights and welfare of the participants. 
Patients with putative Inclusion Body Myositis (IBM) or other forms of myositis provided 
informed consent prior to recruitment and then were screened for participation in this 
study. More specifically, for inclusion in this study, IBM cases met ENMC 2011 criteria 
for clinically or clinico-pathologically defined IBM (Rose and ENMC 2013). Control 
samples were selected from age-matched non-IBM patients, including dermatomyositis, 
polymyositis, immune-mediated necrotizing myopathy, as well as patients with normal 
biopsies or non-inflammatory pathological features. Patient samples with excessive 
fibroadipose replacement or in poor condition were excluded. During a required 
diagnostic biopsy, individuals included in the study donated an extra muscle sample for 
use in xenograft surgeries. Under sterile conditions in the operating room, approximately 
one gram of tissue was removed from muscles having strength of ≥4 (MRC scale (MRC 
1976)). This tissue was then dissected into approximately 7 x 3 x 3mm strips of 
longitudinal fibers and taken immediately to the animal suite for xenografting. 
 
Irradiation of Muscle Biopsy 
Human biopsies treated with irradiation were dissected into two pieces, placed in 
separate 50mL conical tubes containing 10mL of primary muscle media (20% fetal 
bovine serum, 2% chick embryo extract, 1% antibiotic/antimycotic in Hams F10 
Medium), and one tube was treated with a 6.5 Gy dose of ionizing radiation using a Cs-




137 irradiator. This dose was selected based on several studies demonstrating this dose 
was myeloablative, but not likely to severely impact satellite cell activation and thus 
xenograft regeneration (Gulati 1987; Masuda et al. 2015; Giebel et al. 2014; Paix et al. 
2018). This irradiated and untreated muscle was immediately taken to the animal suite 
and xenografted into 8- to 12-week NRG mice.  
 
Animal Husbandry 
All animal experiments were approved by the Johns Hopkins University Institutional 
Animal Care and Use Committee (IACUC) in accordance with the National Institutes of 
Health (NIH) Guide for the Care and Use of Laboratory Animals. Male NOD-Rag1[null] 
IL2rγ[null] (NRG) mice (The Jackson Labs, stock 007799) were used for all experiments. 
Mice were housed in ventilated racks and were given HEPA-filtered, tempered, and 
humidified air as well as reverse osmosis filtered hyperchlorinated water. Mice were 
provided water and an irradiated antibiotic diet (Envigo, TD.06596) ad libitum, and the 
facility provided 14 hours of light to 10 hours of dark as controlled by central timer. For 
xenografted mice treated with 10mg/kg OKT3 (Fisher, 50561956), stock OKT3 was 
diluted with sterile PBS and injected intraperitoneally immediately after the xenograft 
surgery and once weekly until xenograft collection was performed. This dose was 
chosen based on previous studies that demonstrated a dose of 10mg/kg delivered 
intraperitoneally could effectively eliminate CD45+CD3+ cells in the peripheral blood of 
humanized mice (Wunderlich et al. 2014). Control “untreated” mice in OKT3 experiments 
were injected with sterile PBS following the same treatment regimen. 
 
Xenograft Surgery  
For a detailed protocol please refer to Chapter 3. Briefly, 8- to 12-week NRG mice were 




anaesthetized with 1.5% isoflurane, and 0.1mg/kg Buprenorphine (ZooPahrm) was 
administered subcutaneously for pre-emptive analgesia. A vertical incision was made to 
open the skin above the tibial compartment. The tibialis anterior and extensor digitorum 
longus muscles were removed, and pressure applied to achieve hemostasis. A 7 x 3 x 
3mm strip of dissected human muscle was placed in the tibial compartment and ligated 
with non-absorbable suture (6-0 Surgipro, Covidien) to the tendons of the peroneus 
longus muscle. The incision was closed with surgical glue (Histoacryl, Tissue seal) and 
stainless-steel wound clips (AutoClip System, F.S.T). The analgesic Carprofen (Rimadyl, 
Patterson Veterinary) was given subcutaneously after the surgery at a dose of 5mg/kg.  
 
Xenograft Collection and Processing 
For a detailed protocol please refer to Chapter 3. Briefly, NRG host mice were 
anesthetized with 1.5% isofluorane, and the leg was shaved. The skin overlying the 
xenograft was opened by a longitudinal incision from ankle to knee, and the location of 
the graft was determined by the position of the non-absorbable sutures. The xenograft 
was then removed, snap-frozen in 2-methylbutane (Fisher, 03551), and sectioned at 10 
µm using a cryostat (Leica, CM1860 UV). Following collection, the NRG host mice were 
euthanized consistent with AVMA guidelines.  
 
Hematoxylin and Eosin (H&E) Staining  
Fresh, 10µm sections were rehydrated through an ethanol dilution series: three 3-minute 
washes in 100% ethanol (Fisher, BP2818100), a 3-minute wash in 95% ethanol, and a 
3-minute wash in 80% ethanol). Following a 5-minute wash in distilled water (dH2O), 
slides were placed in Hematoxylin (Poly Scientific, s212A) for 3 minutes, washed quickly 
in dH2O, and placed in Tap water for 5 minutes to allow stain to develop. Slides were 




dipped 12 times in acid ethanol (1 mL concentrated Hydrochloric Acid (Fisher, SA48) in 
400mL 70% ethanol), rinsed twice in Tap water for 1 minute, and placed in dH2O for 5 
minutes. Slides were then placed in Eosin (Poly Scientific, s176) for 30 seconds, and 
dehydrated in ethanol. Slides were cleared in xylene (Fisher, X5) and mounted using 
Permount (Fisher, SP15). 
 
Cytochrome C Oxidase/Succinate Dehydrogenase (COX/SDH) Stain 
10µm cryostat sections were obtained and dual-stained for COX/SDH as previously 
described (Loughlin 1993). Briefly, after slides were sectioned, they were immediately 
placed in COX incubating solution. Slides incubated for 2 hours at room temperature, 
and then were rinsed with distilled water. Next, the slides  were placed in SDH 
incubating solution and incubated at 37oC for 2 hours, rinsed in distilled water, 
dehydrated in ethanol (80%, 95%, and 100% Ethanol 5 minutes each), cleared in xylene, 
and mounted using Permount. 
 
Immunohistochemistry  
10µm fresh frozen sections were fixed with ice-cold methanol (Fisher, A412) for 10 
minutes and blocked with anti-mouse IgG (MKB-2215, Vector Laboratories) or with a 
blocking solution consisting of 2% normal goat serum in PBS. The primary antibodies 
used were: anti-human spectrin (NCL-SPEC1, Leica, 1:50), anti-human lamin A/C 
(Abcam, Ab40567, 1:50), anti-human MHC-1 (SC-32235, Santa Cruz, 1:300),  anti-
human p62 (SC-25575, Santa Cruz, 1:250),  anti-embryonic Myosin (eMHC, MYH3) 
(F1.652, DSHB, 1:10), anti-CD3 mouse (M725401-2 ,DAKO, 1:60), anti-CD3 rabbit 
(A0452, DAKO, 1:60), anti-human CD4 (ab133616, abcam, 1:100), anti-CD8 (M710301-
2,DAKO, 1:60), anti-Ki-67 (ab92742, abcam,1:60), anti-CD20 (M0755, DAKO, 1:200), 




anti-CD68 (M0718, DAKO, 1:60), anti-CD138 (M7228, DAKO, 1:100). The secondary 
antibodies used were AlexaFluor 488 goat anti-mouse IgG1, AlexaFluor 594 goat anti-
mouse IgG2b, and AlexaFluor 594 goat anti-mouse IgG1a (all Life technologies, 
1:500). Biotinylated Goat Anti-Rabbit IgG Antibody (BA-1000, Vector Laboratories, 
1:100) and Biotinylated Goat Anti-Mouse IgG Antibody (BA-9200, Vector Laboratories, 
1:100) were used for DAB peroxide staining (SK-4100, Vector Laboratories). Where 
applicable, nuclei were labeled with DAPI in mounting medium (P36931, Invitrogen).   
 
TDP-43 Cryptic Exon Detection 
RNA was extracted from xenograft samples and human biopsies using TRIzol (Fisher 
Scientific, 15596018). A cDNA library was prepared using Protoscript II First Strand 
cDNA synthesis kit with random primers (NEB, E6560L), and cryptic exons were PCR 
amplified using the Dreamtaq Kit (Fisher, K1081P) following the protocol described in 
Figure 4.1. Primer sequences for TDP-43 target genes are summarized in Table 4.1. 
PCR products were visualized via gel electrophoresis on a 2% agarose (Fisher, 17850) 
gel containing 0.5µg/mL Ethidium bromide (Fisher, A25645). 
 









Temperature Duration  
95°C 60 s    
95°C 30 s    
64°C 15 s  40X  
72°C 45 s    
72°C 7 min    
4°C ∞    




Table 4.1 Primer Sequences for Cryptic Exon Detection 
Target Gene Primer Sequences (5’ => 3’) Product Length 
GPSM2 F- AGTGGACATGTGGTGGTAAGAA 
R- GCTTCAAAGAATGACACGCCA 
199bp 
ACSF2 F- TGGTCAGACACAAACCTGG 
R- ACCGAGATGACTGTGGTCAG 
169bp 





T cell Receptor Sequencing 
T cell Receptor (TCR) Sequencing experiments were performed in collaboration with the 
laboratory of Dr. H. Benjamin Larman using the Framework Region 3 (FR3) 
AmplifiKation sequencing (“FR3AK-seq”) method (Montagne et al. 2018). Briefly, RNA 
was TRIzol extracted from human biopsies and xenograft samples, and then reverse 
transcribed using a TCR beta (TCRB) chain constant region reverse primer with 
Superscript III First-Strand Synthesis System (Invitrogen). Primers to FR3 were used to 
PCR amplify all human TCR beta V alleles with KAPA2G Fast Multiplex Mix (Roche). 
Sequencing was performed on a HiSeq 2500, and results were analyzed using MiXCR 
v2.1.11 software (Bolotin et al. 2015) 
 
Flow Cytometry 
Flow Cytometry experiments were performed in collaboration with the laboratory of Dr. 
Armando Villalta as previously described (Villalta et al. 2014). To eliminate non-muscle 




residing immune cells, mice were perfused with PBS and lymph nodes were removed. 
Single-cell suspensions were prepared from the isolated xenografts and incubated with 
anti-CD16/32 (clone 2.4G2) to block Fc receptors. These suspensions were then stained 
with human antibodies for CD3, CD4, CD8, CD28, CD57, and DAPI or Blue-Fluorescent 
Reactive Dye (Invitrogen Life Technologies) to assess cell viability. Analysis was 
performed on live cells on a BD LSRII flow cytometer with FACSDiva software (BD 
Bioscience). Post-acquisition analysis was performed with Flowjo software version 9.1. 
  
Microscopy and Image Analysis 
Fluorescent and transmitted light microscopy was carried out at the Johns Hopkins 
NINDS Multiphoton Imaging Core on a Keyence (BZ-X700) widefield, inverted 
microscope. Image analysis was performed in Fiji (Schindelin et al. 2012). Analysis of 




All statistical analyses were performed using GraphPad Prism version 8.3.1 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. 
One-way ANOVA was used for comparisons between multiples groups, followed by a 
post hoc Tukey test to determine significance of differences between two groups. 
Alternatively, If the standard deviations between the groups were different, one-way 
Brown-Forsythe and Welch ANOVA test was used with the Dunnett’s T3 test for multiple 
comparisons. The nonparametric Mann-Whitney test was used also used to determine 
significance between two groups where noted. Data are presented as means +/- SD 
unless otherwise indicated in figure legends. Significance markers on figures are from 




post hoc analysis (ns, not significant; *p ≤ 0.05, **p ≤ 0.001; ***p ≤ 0.001; ****p ≤ 
0.00001) with values of p ≤ 0.05 considered significant. 
 
 




Chapter 5: A Xenograft Model of 
Inclusion Body Myositis  
5.1 Overview and Aims 
The pathogenesis of IBM has eluded researchers for decades, and is an area of 
considerable debate (Benveniste et al. 2015; Weihl and Mammen 2017; Keller, Schmidt, 
and Lünemann 2017; Greenberg 2019). The presence of highly differentiated CD8+ T-
cells invading healthy-appearing myofibers, the association of IBM with specific HLA loci 
and other autoimmune disorders, and the presence of autoantibodies in IBM support an 
autoimmune basis for the disease. However, the fact that immunosuppression has failed 
to show clinical benefit, the presence of protein aggregates (e.g. p62 and TDP-43) 
commonly found in neurodegenerative diseases, and the association with aging suggest 
the possibility that IBM is primarily a degenerative disease. Taken together, the 
pathogenesis of IBM is likely multifactorial with contributions from aging, genetic 
background, and environmental factors, and thus may be a combination of autoimmune 
and degenerative pathophysiologic processes. The absence of an animal model for IBM 
has hindered our progress in understanding the pathogenesis of IBM, and this study 








5.2 Inclusion criteria and patient characteristics 
Patients with putative IBM or other forms of myositis or myopathy provide informed 
consent prior to recruitment and then are screened for participation in this study (Table 
5.1).  Older patients undergoing muscle biopsy were preferentially recruited for this study 
to increase the likelihood of obtaining age-matched controls. IBM cases meet ENMC 
2011 criteria for clinically or clinico-pathological defined sporadic IBM (Rose and ENMC 
2013). Control samples are selected from non-IBM patients, including dermatomyositis, 
polymyositis, immune-mediated necrotizing myopathy, as well as patients with normal 
biopsies or mild, non-inflammatory pathological features. Patient samples with excessive 
fibroadipose replacement or in poor condition are not used for xenograft surgeries. 
Control patients are divided into non-myositis or myositis groups based on the absence 
or presence of T cells within the diagnostic biopsy respectively. The typical pathologic 
diagnoses of “non-myositis control” (NMC) biopsies include normal muscle, mild 
myopathic features (e.g. scattered internalized nuclei), mild neurogenic atrophy, and/or 
mitochondrial abnormalities. The “myositis control” (MC) biopsies show perifascicular 
inflammation, mild necrosis, myophagocytosis, and/or fasciitis. The IBM biopsies show 
characteristic features of IBM, including endomysial inflammation, primary invasion of 
myofibers by CD3+ T cells, COX-deficient fibers, and/or rimmed vacuoles. The sex and 
disease duration of the patients as well as the strength of the biopsied muscle are not 
significantly different between control and IBM patients (Table 5.1). However, the IBM 
patient population is significantly older than both control groups (non-myositis controls 
(NMC) vs IBM, p = 0.0125; myositis controls (MC) vs IBM, p = 0.0088) (Table 5.1). The 
majority of skeletal muscle biopsies used in xenograft surgeries were obtained from the 
biceps (46.15%) or rectus femoris (30.77%).  






Table 5.1 Characteristics of xenograft study population   
 
Table 5.1 A summary of clinical, demographic, and biopsy details of patients involved used in this 
study. The disease duration was determined from the time of symptom onset—according to the 
patient’s medical records—to the time the diagnostic biopsy was performed. The strength of the 
biopsied muscle was based on the Medical Research Council (MRC) scale out of five (MRC 
1976). Mann-Whitney test was used to determine significance for the following features: age, 
disease duration, and strength of biopsied muscle. Fisher’s exact test was used to determine 
significance for the sex ratio of the patient population (Non-myositis control (NMC); Myositis 























n (%) 17 (65.38%) 3 (50%) 3 (50%) 11 (78.57%) 0.3027 0.3027 
Age (yrs.), 
mean ± SD 64.27 ± 10.23 58.5 ± 10.9 57.3 + 9.58 69.7 + 7.13 0.0125* 0.0088** 
Disease 
duration 
(yrs.),   
mean ± SD 
4.77 ± 5.98 5.67 ± 4.84 6.50 ± 11.57 3.64 ± 2.27 0.4503 0.3313 
Biopsy 
location,    
n (%) 
      
-   Biceps 12 (46.15%) 3 (50%) 1 (16.67%) 8 (57.14%)   
-   Rectus    
    femoris 8 (30.77%) 2 (33.33%) 3 (50%) 3 (21.43%) 
  
-   Vastus  
    lateralis 3 (11.54%) 1 (16.67%) 1 (16.67%) 1 (7.12%) 
  
-   Deltoid 3 (11.54%) 0 (0%) 1 (16.67%) 2 (14.28%)   
Number of 



































5.3 IBM xenografts regenerate robustly in NRG mice 
Our data demonstrate that IBM xenografts successfully regenerate comparably to both 
non-myositis and myositis control xenografts (Figure 5.1). Histological and 
immunofluorescent stains both show numerous regenerated human fibers (Figure 
5.1A), and there are no significant differences in the number of regenerated fibers 
between any of the three groups (Figure 5.1B). In addition, the percent of embryonic 
myosin (eMHC) positive fibers is unchanged, indicating that the process of myofiber 
maturation as assessed by the turnover of eMHC is unaffected (Schiaffino et al. 2015) 
(Figure 5.1D). There is a moderate increase in myofiber density, as determined by the 
percent of the xenograft area covered by myofibers, observed in IBM xenografts in 
comparison to non-myositis control xenografts (p = 0.0315) (Figure 5.1C). This can be 
explained by a corresponding increase in the median cross-sectional area (CSA) of IBM 
xenografts in comparison to both non-myositis control (p < 0.0001) and myositis control 
xenografts (p = 0.0420) (Figure 5.1E). Overall, these data show that IBM patient muscle 
is capable of forming robust human xenografts, even from patients showing moderate to 
severe IBM pathology. This is important on two fronts: first and foremost, this 
demonstrates feasibility of this model, and second, it demonstrates that IBM muscle is 
















































Figure 5.1 (A) Representative images of non-myositis control, myositis control, and IBM 
xenografts stained with H&E, human spectrin (red), human lamin A/C (green), embryonic myosin 
(eMHC) (green), and DAPI (blue). Quantification of the number of fibers over the xenograft area 
(B), the fiber density of the xenografts as determined by the percentage of the xenograft area 
covered by myofibers (C), the percent of eMHC+ fibers (D), and the median cross-sectional area 
(CSA) of myofibers within the xenografts (E). For all graphs, each point denotes one xenograft 
(non-myositis control, n=14; myositis control, n=14; IBM xenografts, n=31) and for all p-values 
determined by Dunnett’s T3 test following one-way Brown-Forsythe and Welch ANOVA: *p ≤ 
0.05. 




5.4 IBM xenografts recapitulate disease pathology 
Once it was established IBM muscle could regenerate in host mice, the next step was to 
assess these xenografts for features of IBM pathology. Namely, we examined xenografts 
for degenerative features such as protein aggregation and mislocalization as well as 
inflammatory features such as endomysial inflammation and primary invasion of non-
necrotic fibers.  
 
Protein aggregation and mislocalization 
To assess the IBM xenografts for degenerative features of disease we first performed 
immunostaining for p62, an autophagic adaptor that binds to ubiquitinated protein 
aggregates and is commonly seen aggregated in IBM muscle (Hiniker et al. 2013). We 
found positive staining at 10-months within IBM xenografts, but not myositis controls 
(Figure 5.2A). These p62-positive fibers are rare and have not been observed in earlier 
collections. Another degenerative feature observed in IBM patient muscle is the 
sarcoplasmic mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43) 
(Salajegheh et al. 2009; Hiniker et al. 2013). One of the essential nuclear functions of 
TDP-43 is to act as a splice repressor of cryptic exons (Jonathan P. Ling 2015). When 
TDP-43 is mislocalized from the nucleus, these cryptic exon sequences are included in 
mRNA transcripts and can be detected via RT-PCR using primers designed to the 
junctions between cryptic exons and adjacent exons (Figure 5.2B). We tested non-
myositis, myositis, and IBM patient biopsies for cryptic exon expression from three TDP-
43 target genes: GPSM2, ACSF2, and HDGFRP2 (Figure 5.2C). The majority (9 out of 
11, 81.82%) of the IBM patient biopsies showed cryptic exon expression, and none (0 
out of 7, 0%) of the control patients showed cryptic exon expression (Figure 5.2C). In 




addition, we have detected GPSM2 and ACSF2 cryptic exon expression within 8-month 
and 10-month IBM xenografts from three different IBM cases, but not in non-myositis 
control xenografts (Figure 5.2D,E). Cryptic exon expression in IBM xenografts always 
corresponds to the patient biopsy; i.e. only human biopsies showing cryptic exon 
expression result in xenografts with cryptic exon expression. Examining cryptic exon 
expression longitudinally within one case reveals that although cryptic exon expression 
cannot be detected at 4-months (0/2 xenografts), by 8-months expression can be 
detected (3/4 xenografts) (Figure 5.2E), which suggests that this feature of IBM 
xenografts develops over time. Of note, we have not observed an obvious 
mislocalization and aggregation of TDP-43 in the sarcoplasm of IBM xenografts. 
However, these data show that TDP-43 nuclear function is likely impaired, and the 
protein is likely mislocalized in IBM xenografts, but not to the same extent as observed in 





















































Figure 5.2 (A) Staining of autophagic adaptor p62 within patient biopsies and 10-month xenograft 
collections from myositis control and IBM xenografts. (B) Using primer pairs (arrows) designed to 
the junction of cryptic exon (CE) sequences, cryptic exon expression from TDP-43 target genes 
can be detected using RT-PCR. (C) Cryptic exon expression from TDP-43 target gene GPSM2 
(G), ACSF2 (A), and HDGFRP2 (H) detected in IBM patient biopsies. No cryptic exon expression 
was detected in biopsies from non-myositis controls patients, or myositis control patients 
diagnosed with Dermatomyositis (DM) or immune mediated necrotizing myopathy (IMNM). (D) 
Cryptic exon expression from GPSM2 (G) detected in IBM patient biopsies and xenografts, but 
not non-myositis control biopsy or xenografts (B = patient biopsy). (E) Cryptic exon expression 
from TDP-43 target gene GPSM2 (G) and ACSF2 (A) detected in IBM xenografts at 8-months, 
but not 4-month collections (B = patient biopsy). 





Mitochondrial abnormalities are a widely underappreciated feature of IBM pathology, and 
are not included in most diagnostic criteria for IBM. However, scattered cytochrome c 
oxidase (COX)-deficient fibers can be seen in the vast majority of patient muscle 
biopsies (Dahlbom, Lindberg, and Oldfors 2002; Joshi et al. 2014; Catalan-Garcia et al. 
2016). To assess IBM xenografts for this pathological feature, we carried out dual COX 
and succinate dehydrogenase (SDH) histological stains on 4-month non-myositis, 
myositis, and IBM xenografts. We find that the number of COX-deficient fibers is 
significantly increased in IBM xenografts in comparison to both non-myositis control 
xenografts (p = 0.0010) and myositis control xenografts (p = 0.0256) (Figure 5.3A,B). 
These findings indicate that this feature of IBM pathology is also recapitulated in our IBM 















































Figure 5.3 (A) Representative images of dual COX/SDH stains of 4-month non-myositis control, 
myositis control, and IBM xenografts. (B) Quantification of the number of COX-deficient fibers in 
each group; each point denotes one xenograft (non-myositis control n = 12, myositis control n= 
13, IBM n = 25). Groups were compared using Brown-Forsythe and Welch one-way ANOVA with 










Endomysial inflammation and primary invasion in IBM xenografts 
In addition to these degenerative characteristics, several inflammatory features of IBM 
are also recapitulated in IBM xenografts (Figure 5.4). Non-myositis and myositis control 
xenografts show typical MHC-I staining around capillaries; however, IBM xenografts 
show a dramatic sarcoplasmic upregulation of MHC-1 (Figure 5.4A). We find that this 
upregulation corresponds to the presence of CD3+ T cells within IBM xenografts (Figure 
5.4A). In comparison to non-myositis control xenografts, both myositis control xenografts 
(p < 0.0001) and IBM xenografts (p < 0.0001) show significantly higher levels of CD3+ T 
cells (Figure 5.5B). Despite the similar levels of inflammation in both IBM and myositis 
control xenografts, examples of primary invasion of non-necrotic fibers are only 
observed in IBM xenografts (Figure 5.5C). Further staining shows a variety of different 
human immune cells persist within IBM xenografts, including helper (CD4+) and 
cytotoxic (CD8+) T cells, in addition to B cells (CD20+), macrophages (CD68+), and rare 
plasma cells (CD138+) (Figure 5.4D).  
 
Remarkably, the majority of CD8+ T cells within IBM xenografts were found to be 
proliferative at 4-months, and this proliferation is significantly reduced by 6-months (p < 
0.0001) and remains low at 8.5-months (p < 0.0001) (Figure 5.5A,B). The nature of the 
immune cells present with IBM patient muscle has been the focus of numerous studies. 
The majority of IBM muscle biopsies show oligoclonal populations of T cells, indicating 
that recognition of an unknown antigen is likely occurring (O'Hanlon et al. 1994; 
Lindberg, Oldfors, and Tarkowski 1994; Fyhr et al. 1997; Salajegheh et al. 2007). These 
clonal population of T cells persist over time, experience repeated antigen stimulation 
indicated by their loss of CD28 expression, and become highly differentiated and 




cytotoxic as shown by the expression of markers such as CD57 and KLRG1 (Müntzing 
et al. 2003; Pandya et al. 2010; Greenberg et al. 2016; Greenberg et al. 2019).  
 
To better characterize the human immune cells within IBM xenografts, we have 
performed flow cytometry and T cell receptor (TCR) sequencing. Flow cytometry 
experiments have shown increased numbers of human CD45+ lymphocytes in an IBM 
xenograft in comparison to a myositis control xenograft (Figure 5.5C). The IBM 
xenograft had high levels of both CD4+ T cells and CD8+ T cells whereas the myositis 
control only had very low numbers of CD8+ cells (Figure 5.5C). Finally, many CD4+ and 
CD8+ T cells in the IBM xenografts were CD57+, and some of the CD8+ cells were 
CD28-CD57+ indicating they were antigen experienced, which was not the case in the 
myositis control xenograft (Figure 5.5C). These populations of cells mirror what has 
been found in IBM patient biopsies. 
 
To examine whether the T cells in IBM xenografts are oligoclonal, we used Framework 
Region 3 AmplifiKation sequencing (FR3AK-seq), a multiplex PCR-based approach to 
determine TCR repertoires (Montagne et al. 2018). This technique revealed that T cells 
within IBM xenografts are clonally restricted and contain hyperexpanded populations of 
T cells (Figure 5.5D). In addition, T cells within two xenografts showed restricted J gene 
(TRBJ2-3*01) usage, which was also observed three IBM patients (Figure 5.5E). Taken 
together, these data indicate that potentially disease relevant immune cells persist in 
IBM xenografts, and, as this model recapitulates the inflammatory and degenerative 
features of IBM, it provides a platform for therapeutic testing.   
  






































Figure 5.4 (A) Representative MHC-I and CD3 stains of 4-month non-myositis control, myositis 
control, and IBM xenografts. (B) Quantification of the number of CD3+ T cells over the xenograft 
area. Each point denotes one xenograft (non-myositis control, n=14; myositis control, n=14; IBM 
xenografts, n=31), and one-way ANOVA with Tukey’s multiple comparison test was used to 
determine p-values ( ****p<0.0001). (C) H&E and CD3 stains showing an example of primary 
invasion of a non-necrotic fiber in a 4-month IBM xenograft. (D) Representative stains of CD4, 
CD8, CD20, CD68, and CD138 from a 4-month IBM xenograft. 


















































Figure 5.5 (A) Ki-67 (red) and CD8 (green) staining of 4-month, 6-month, and 8.5-month IBM 
xenografts. (B) Quantification of the percent of CD8+ T cells that show positive Ki-67 staining in 




4-month, 6-month, and 8.5-month IBM xenografts. Fisher’s exact test was used to determine 
significance (****p < 0.0001). (C) Flow cytometry experiments comparing a myositis control 
xenograft and an IBM xenograft using human specific CD45 (hCD45) to analyze CD4+ and CD8+ 
populations of human T cells in xenografts. CD28 and CD57 populations were also examined (D) 
Analysis of TCR repertoire of 14 IBM muscle biopsies shows that most have primarily “large or 
“hyperexpanded” T cell clones. 5 xenografts samples from case 1 (1A-1F) and 7 samples from 
case 2 (2A-2G) from 3-11 month timepoints all show primarily hyperexpanded T cell clones. (E) 
Multiple sequence alignment (by MUSCLE) of a TCR clone found in xenografts from 2 patients 















Chapter 6: Preclinical Testing in 
the IBM Xenograft Model 
6.1  Overview and Aims 
A fundamental stumbling block to the development of therapies for IBM has been the 
lack of an animal model: a problem we have aimed to address with our IBM xenograft 
model. The second goal of this project is to determine the feasibility of using this model 
to carry out preclinical studies. A central question in IBM is whether inflammation drives 
degeneration or is secondary to it. Recently, highly differentiated effector CD8+ T cells 
present in IBM muscle have been suggested to be refractory to conventional 
immunotherapy, and several companies are developing targeted approaches to deplete 
this subpopulation of T cells for therapeutic development in IBM (Greenberg et al. 2016; 
Greenberg et al. 2019).  Our xenograft model may be an ideal model to test this 
hypothesis in vivo. If depleting T cells rescues degenerative pathological features, this 
would provide direct evidence that T cells are necessary for myofiber degeneration in 
IBM. In contrast, if depleting T cells (including the putative refractory highly-differentiated 
subset) has no effect on degenerative pathology, this would suggest that this is unlikely 
to be a successful therapeutic approach. If these experiments are successful, they hold 
promise for directing therapeutic development in IBM.  
 




6.2 Irradiation of IBM Xenografts 
Our initial studies involved the use of ex vivo irradiation to eliminate immune cells within 
the human biopsy. Ionizing radiation causes double-strand breaks in DNA either directly 
or indirectly via reactive oxygen species (ROS). DNA repair mechanisms for correcting 
double-strand breaks are error-prone and typically result in chromosomal aberrations 
and rearrangements that can be observed in the first metaphase after irradiation (Hall 
and Kereiakes 2001). When cells attempt to proliferate in the face of this DNA damage, 
they enter cell cycle arrest, and, if the DNA damage cannot be repaired, apoptosis or 
other cell death pathways are triggered and the cells are eliminated (Mladenov et al. 
2016). In particular, T cells are moderately radiosensitive and typically die via necrosis 
when challenged with a dose over 2 Gy (Falcke et al. 2018).  We hypothesize that low 
dose radiation may deplete inflammatory cells without inhibiting proliferation of muscle 
stem cells (satellite cells), and thereby allow us to test our central hypothesis that T cells 
drive degenerative pathology in IBM. 
 
Patient Characteristics  
To carry out these experiments, muscle biopsy specimens from six patients (4 IBM, 2 
controls (Table 6.1)) were treated with a 6.5 Gy dose of ionizing radiation. This dose 
was selected based on several studies demonstrating that this dose was myeloablative, 
without severely impacting satellite cell activation (Gulati 1987; Masuda et al. 2015; 
Giebel et al. 2014; Paix et al. 2018; Falcke et al. 2018). All IBM patients met ENMC 2011 
criteria for clinico-pathologically or clinically defined IBM (Rose and ENMC 2013). The 
IBM biopsies showed characteristic pathological features including endomysial 
inflammation and primary invasion as well as vacuoles and mitochondrial pathology 




(Table 6.1, Figure 6.1). The control case 14 biopsy showed scattered myofiber 
degeneration and necrosis (Figure 6.1E), and rare scattered inflammatory cells (Figure 
6.1H). There were no examples of primary invasion, and the GT stain did not show red-
rimmed vacuoles or ragged-red fibers (Figure 6.1K). The control case 15 biopsy showed 
rare angular atrophic fibers indicating mild neurogenic atrophy, and there was no 






















Table 6.1 Patient Characteristics - Irradiation Experiments 
 
Table 6.1 A summary of clinical demographics, histological features, and clinical diagnosis of 
patients involved in irradiation experiments. The average age of the IBM patients was 70.25 years 
and the average age of controls was 64 years. One of the four IBM patients was female, and both 
control patients were female. The majority of the muscle biopsies were taken from the biceps. 
One IBM patient had a vastus lateralis biopsy, and one control had a rectus femoris biopsy. The 
biopsy location is followed in parentheses by the strength of the biopsied muscle based on the 
Medical Research Council (MRC) scale out of five (MRC 1976). The IBM biopsies showed 
characteristic pathological features including endomysial inflammation and invasion as well as 
rimmed vacuoles. One control showed a mild necrotizing myopathy with limited immune cells, 









Histological Features of Biopsy 
5 Male 77 sIBM Biceps 
(5) 
Moderate inflammatory myopathy with 
myofiber degeneration, MHC-I 
upregulation, necrosis, regeneration, 
endomysial inflammatory cells, and 
frequent red rimmed vacuoles. In addition, 
there is mild neurogenic atrophy and 2 
dozen COX-negative fibers. 
6 Male 74 sIBM Vastus 
lateralis 
(5) 
Chronic inflammatory myopathy with red 
rimmed vacuoles, myofiber degeneration, 
endomysial inflammation and primary 
invasion, numerous COX-negative fibers, 
and mild neurogenic atrophy.  
19 Female 66 sIBM Biceps 
(4+) 
Severe, chronic inflammatory myopathy 
with myofiber degeneration, necrosis, 
regeneration, endomysial inflammation and 
primary invasion, and vacuoles. There is 
also mild neurogenic atrophy and several 
COX-negative fibers. 
20 Male 66 sIBM Biceps 
(5) 
Moderate inflammatory myopathy with 
myofiber degeneration, necrosis, 
regeneration, endomysial inflammation and 
primary invasion, and frequent vacuoles. In 
addition, there is mild neurogenic atrophy 
and innumerable COX-negative fibers. 




Mild necrotizing myopathy and mild type 2 
atrophy. There is scattered myofiber 
degeneration and necrosis, rare scattered 
inflammatory cells and no primary 
inflammation. 






Mild Neurogenic atrophy. No myofiber 
degeneration, regeneration, or necrosis, 
and no inflammatory cells are present. 

























Figure 6.1 Paraffin (A-C), H&E (D-F), CD3 (G-I), and gomori trichrome (GT) (J-L) stains showing 
representative histology from IBM case 19, and control cases 14 and 15. The IBM case 19 biopsy 
shows severe endomysial inflammation and primary invasion of non-necrotic fibers ( A,D,G), and 
vacuoles (J, arrow). The control case 14 biopsy shows scattered myofiber degeneration and 
necrosis (E), and rare scattered inflammatory cells (H). There is no primary invasion, and the GT 
stain does not show vacuoles or ragged-red fibers (K). The control case 15 biopsy shows rare 
angular atrophic fibers (F) indicating mild neurogenic atrophy. There is no myofiber degeneration, 
regeneration, or necrosis, and no inflammatory cells are present (C,F,I,L). 
 




Irradiation of xenografts severely impairs control regeneration and does not 
significantly reduce inflammation 
At 4 months, irradiated IBM xenografts show moderately improved regeneration (p = 
0.0309), but no significant reduction in the number of CD3+ T cells (Figure 6.2, Figure 
6.3A,B). Interestingly, while the regeneration of control xenografts was severely 
impaired by irradiation (p = 0.0004) (Figure 6.2D, Figure 6.3A), irradiation led to a small 
but significant improvement in muscle regeneration in IBM xenografts. Similarly, while 
there is also a reduction in the median CSA of regenerated myofibers in the irradiated 
control xenografts (p = 0.0023), there is no effect of radiation on myofiber size in IBM 
xenografts (Figure 6.3C). These data demonstrate that even low dose irradiation can 
impair regeneration of control xenografts, likely by impacting proliferating satellite cells. It 
is interesting that IBM xenografts appear to be resistant to this irradiation-induced 
impairment in myoregeneration. It has been reported that the number of satellite cells is 
increased in IBM patient muscle, and expression of MyoD is reduced whereas Myogenin 
is strongly upregulated (Hollemann et al. 2008). MyoD is a transcription factor that drives 
proliferation of satellite cells and, conversely, the transcription factor Myogenin drives 
differentiation (Zammit 2017). Taken together, this describes an increased population of 
satellite cells primed for differentiation instead of proliferation, which may explain why 
IBM xenografts were not negatively impacted by irradiation and instead showed 
moderate improvement in the number of regenerated fibers. The number of control (n=2) 
and IBM (n=4) patients used in these studies was small, however, this may be an 
interesting area for future investigation. In addition, despite the small patient population, 
the inability of irradiation to significantly reduce T cell number in xenografts suggests that 
a more targeted approach is needed to test the effects of T cells on IBM pathology. 




Figure 6.2 Irradiation of xenografts severely impairs control regeneration and does not 




























Figure 6.2 Lamin A/C (green), spectrin (red), eMHC (green), DAPI (blue), and CD3 staining of 
control untreated xenografts (A-C), control irradiated xenografts (D-F), IBM untreated xenografts 
(G-I), and IBM irradiated xenografts (J-L). All xenografts were collected at 4 months. 






















Figure 6.3 Quantification of the number of fibers over the xenograft area (A), the number of 
CD3+ T cells over the xenograft area (B), the median cross sectional area (CSA) of myofibers 
within the xenografts (C), and the fiber density of the xenografts as determined by the percent of 
the xenograft area covered by myofibers (D). For all graphs, each point denotes one xenograft 
(control untreated n =4, control irradiated n = 4, IBM untreated n = 9, IBM irradiated n = 9) and p-
values determined were determined by Tukey’s multiple comparisons test: ns, not significant; *p ≤ 
0.05; **p ≤ 0.01; ***p ≤ 0.001. 




6.3 Depleting T cells in IBM Xenografts with 
monoclonal CD3 antibody OKT3 
A monoclonal antibody is produced by a single B cell targeting one specific antigen, and 
this specificity has been adapted for clinical use in the form of chimeric and humanized 
monoclonal antibodies (Zhang et al. 2018). Monoclonal antibodies can be used to 
deplete specific immune cells via induction of apoptosis or by antibody-dependent cell-
mediated cytotoxicity (ADCC).  One of the first human monoclonal antibodies created 
was OKT3 (generic name: Muromonab-Cd3), which recognizes a nonpolymorphic 
subunit of the human TCR: CD3ε (Kung et al. 1979; Kjer-Nielsen et al. 2004). OKT3 was 
the first monoclonal antibody approved by the US FDA for therapy in humans to prevent 
acute rejection in organ transplant patients by blocking cytotoxic T cell function (Zhang 
et al. 2018). In addition, OKT3 treatment can prevent graft-versus-host disease (GVHD) 
by ablating human T cells in mice engrafted with human hematopoietic cells (Wunderlich 
et al. 2014). We hypothesized that treating xenografted mice with OKT3 would 
specifically eliminate T cells within the grafts, which would enable us to study the effect T 
cells may be exerting on xenograft regeneration and determine if aspects of IBM 
degenerative pathology are dependent on T cells.  
 
Patient Characteristics 
Muscle biopsies from three patients with clinico-pathologically or clinically defined IBM 
were used to carry out these OKT3 experiments (Table 6.2). All IBM patient biopsies 
showed moderate to severe endomysial inflammation, numerous examples of primary 
invasion of non-necrotic fibers, and mitochondrial pathology (Figure 6.4). Of note, IBM 
case 36 did not have rimmed vacuoles, but studies have found that up to 20% of 




patients with typical clinical features of IBM do not have rimmed vacuoles (Chahin and 
Engel 2008; Ikenaga et al. 2017). 
 
 








Histological Features of Biopsy 
23 Male 64 sIBM Biceps 
(4+) 
Severe, chronic inflammatory myopathy 
with myofiber degeneration, necrosis, 
regeneration, and rimmed vacuoles. 
There is diffuse endomysial 
inflammation and many examples of 
primary invasion. MHC-1 is upregulated 
and innumerable COX-negative fibers. 
26 Male 75 sIBM Biceps 
(4) 
Moderate inflammatory myopathy with 
endomysial and perivascular 
inflammation, examples of primary 
invasion, many COX-negative fibers, 
MHC-1 is diffusely upregulated, red-
rimmed vacuoles, and neurogenic 
atrophy.  
36 Male 64 sIBM Rectus 
Femoris 
(5) 
Moderately severe, chronic inflammatory 
myopathy with myofiber degeneration, 
necrosis, and regeneration. There are 
numerous foci of endomysial 
inflammation, primary invasion, and. 
Particularly striking are mitochondrial 
abnormalities with innumerable COX-
negative fibers and several ragged red 
fibers. There were no vacuoles seen, 
and there is mild acute neurogenic 
atrophy 
 
Table 6.2 A summary of clinical demographics, histological features, and clinical diagnosis of IBM 

































Figure 6.4 Paraffin (A-C), H&E (D-F), CD3 (G-I), Gomori trichrome (GT) (J-L), and dual COX-
SDH (M-O) stains showing representative histology from IBM cases 23, 26, And 36. All biopsies 
show endomysial inflammation and primary invasion (A-I). In addition, all biopsies show 
innumerable COX deficient fibers (M-O). The IBM cases 23 and 26 show rimmed vacuoles (J,K 
arrows), but vacuoles are absent in IBM case 36 (L). 




OKT3 successfully eliminates T cells from xenografts, but myofiber regeneration 
is unaffected 
Xenografted mice are treated weekly via intraperitoneal injection with 10mg/kg OKT3 as 
this treatment regimen has been shown to effectively ablate human T cells in vivo 
(Wunderlich et al. 2014). OKT3 dramatically reduced the number of CD3+ T cells at both 
2-month (p = 0.0286) and 4-month (p <0.0001) timepoints (Figure 6.5A-E). Untreated 
IBM xenografts show numerous foci of endomysial inflammation and high numbers of 
CD3+ T cells (Figure 6.5A,B), whereas OKT3 treated xenografts show very low 
numbers of scattered CD3+ T cells (Figure 6.5 C,D).  
 
Although treatment with OKT3 was highly effective in depleting T cells, myofiber 
regeneration was unchanged between control and treatment groups (Figure 6.6). The 
number of regenerated fibers, their median CSA, and the fiber density of the xenografts 
are not significantly different (Figure 6.6 E,F,H). In addition, OKT3 treatment did not 
impact the number of eMHC+ fibers (Figure 6.6G), indicating that the process of 
myofiber maturation was unchanged (Schiaffino et al. 2015). The human biopsies 
display fiber size variability as expected for IBM patients (Figure 6.7 A,C,E), and the 
myofiber CSA distributions do not differ between OKT3 treated and untreated xenografts 
(Figure 6.7B,D,F). In healthy muscle, the inflammatory response to muscle injury is a 
highly complex and coordinated process involving cells from both the innate and 
adaptive immune system (Tidball 2017). Fortunately, these data demonstrate that the 
presence of T cells within IBM xenografts does not significantly impair myofiber 
regeneration in our model and allows us to examine if aspects of IBM pathology are 
influenced by the presence or absence of T cells. 
  
















































Figure 6.5 Representative H&E (A,C) and CD3 (B,D) stains of 4-month untreated (A,B) and 
OKT3 treated (C,D) xenografts from IBM case 26. Quantification of the number of CD3+ T cells 
over the xenograft area (E) shows the number of T cells is significantly reduced both at 2 months 
(p=0.0286) and 4 months (p<0.0001) by OKT3 treatment. For all graphs, each point denotes one 
xenograft (2 month untreated n = 4 , 2 month OKT3 n = 4 ,  4 month untreated n = 11, 4 month 
OKT3 n = 12) and Mann-Whitney U test was used to determine p-values (*p<0.05, ****p<0.0001). 
 


























Figure 6.6 Representative lamin A/C (green), spectrin (red), eMHC (green), and DAPI (blue) 
stains of 4-month untreated (A,B) and OKT3 treated (C,D) xenografts from IBM case 36. 
Quantification of the number of fibers over the xenograft area (E), fiber density (F), percent of 
eMHC+ fibers (G), and median fiber CSA (H) show OKT3 treatment did not significantly impact 
regeneration or fiber morphology. For all graphs, each point denotes one xenograft (2 month 
untreated n = 4 , 2 month OKT3 n = 4 ,  4 month untreated n = 11, 4 month OKT3 n = 12) and 
Mann-Whitney U test was used to test for significance (ns, not significant). 






























Figure 6.7 Histograms of the cross-sectional area (CSA) of the Case 23 (A,B), Case 26 (C,D), 
and Case 36 (E,F) human biopsies and the 4-month untreated and OKT3 treated xenografts. The 
distribution of the CSAs of the untreated and OKT3 treated xenografts are similar and are skewed 
right. 




T cells drive mitochondrial pathology in IBM Xenografts 
Dual COX/SDH staining was carried out on all 4-month xenograft samples from cases 
23, 26, and 36 (Figure 6.8A,B). The untreated xenografts have an average of 3.27 
COX-deficient fibers and the OKT3 treated xenografts had an average of 1.55 COX-
deficient fibers, which was a significant decrease (p = 0.0291) (Figure 6.8C). These data 
indicate that T cells are driving mitochondrial pathology in IBM xenografts. Indeed, we 
find that the number of COX-deficient fibers is significantly correlated to the number of 
CD3+ T cells in IBM xenografts (p = 0.0203) (Figure 6.8D). These data support previous 
work demonstrating positive correlations between the number of COX-deficient muscle 
fibers and the severity of inflammation in IBM patient biopsies (Rygiel et al. 2015). 
Interestingly, this relationship is not observed in control myositis xenografts that show 






























Figure 6.8 Dual COX-SDH stain of untreated (A) and OKT3 treated (B) 4-month IBM xenografts 
from IBM case 36. COX-deficient fibers appear light to dark blue. (C) Quantification of the number 
of COX-deficient fibers in 4-month xenografts, each point denotes one xenograft (untreated n = 
11, OKT3 n =12). Mann-Whitney test was used to determine significance (*p ≤ 0.05). (D) 
Correlation of the number of CD3+ T cells to the number of COX-deficient fibers in 4-month 
xenografts, each point denotes one xenograft (non-myositis control n=12 , myositis control n=13, 
IBM n=25). Spearman rank correlation was used to determine all p-values (*p ≤ 0.05). 





Chapter 7: Discussion and Future 
Directions 
 
Human Skeletal Muscle Xenografts are a novel way to model IBM 
The intertwined degenerative and inflammatory pathological features of IBM have fueled 
the debate underlying the pathogenesis of the disease and have stymied attempts to 
create comprehensive laboratory models (Keller, Schmidt, and Lünemann 2017; 
Greenberg 2019). Skeletal muscle xenografts provide an exciting new avenue to model 
both inherited and acquired muscle diseases (Zhang et al. 2014; Britson et al. 2019). 
These xenografts can recapitulate the complex genetic and epigenetic abnormalities that 
exist in human disease that may never be reproducible in other animal models, and 
xenografts form a complete in vivo system for modeling disease. There was an initial 
concern that IBM patient muscle would not be competent to form xenografts as some 
studies suggest muscle regeneration may be impaired in IBM. First, in vitro studies have 
shown that myoblasts isolated from IBM patients proliferate at a slower rate than age-
matched controls, and show telomere shortening, indicative of premature senescence 
(Morosetti et al. 2010). In addition, skeletal muscle regeneration is highly regulated by 
the immune system, and the chronic inflammation in IBM has been suggested to 
negatively influence muscle regeneration (Loell and Lundberg 2011; reviewed in: Tidball 
2017; Sass et al. 2018; Howard et al. 2020). Finally, aging itself diminishes the 
regenerative capacity of skeletal muscle, resulting in the loss of muscle mass and 




strength observed in elderly populations termed sarcopenia (Suetta et al. 2013; Dodds et 
al. 2015; Joanisse et al. 2017).  
 
In contrast to these studies suggesting muscle regeneration may be impaired in IBM, 
one study showed an increased expression of myogenic regulatory factor myogenin in 
IBM patient satellite cells and reported higher numbers of satellite cells and regenerating 
fibers in IBM patient biopsies in comparison to age-matched controls (Wanschitz et al. 
2013). Our data show that IBM patient muscle can robustly regenerate in NRG host mice 
to form skeletal muscle xenografts. In fact, IBM xenografts showed significantly higher 
fiber density and increased median CSA in comparison to non-myositis control 
xenografts. These results show that our xenograft approach to modeling IBM is feasible 
despite previous studies showing reduced proliferation of IBM myoblasts, the persistent 
chronic inflammation in IBM xenografts, and the significantly elevated age of the IBM 
patients in our xenograft study in comparison to controls. 
 
Importantly, several degenerative and inflammatory pathological features of IBM are 
recapitulated in this xenograft model. First, rare fibers with p62 aggregates are observed 
in 10-month IBM xenografts, but not in 10-month myositis control xenografts. It has been 
reported that the combination of p62 and TDP-43 staining is both sensitive and specific 
for IBM, and these two markers are seen aggregated in 12% of patient myofibers 
(Dubourg et al. 2011; Hiniker et al. 2013). Although these aggregates are rarely seen in 
other inflammatory myopathies, they are frequently observed in neurodegenerative 
diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD), 
which lends support to the idea that IBM is primarily a degenerative disease (Cortese et 
al. 2014; Chornenkyy, Fardo, and Nelson 2019). In our neuromuscular biopsy laboratory, 




we have difficulty detecting TDP-43 cytoplasmic aggregates and loss of nuclear TDP-43 
in IBM muscle biopsies, and as a result, we are unable to reliably quantify sarcoplasmic 
TDP-43 aggregation in IBM xenografts.  However, a sensitive way to detect nuclear loss 
of TDP-43 is through the assessment of cryptic exon expression (Jonathan P. Ling 2015; 
Jeong et al. 2017). One of the normal functions of TDP-43 is to act as a splice repressor 
of these cryptic exons, and their incorporation in mRNA transcriptions can be detected 
using a simple RT-PCR assay (Jonathan P. Ling 2015; Jeong et al. 2017). Of note, 
cryptic exon incorporation can be detected in hippocampal samples from AD patients 
lacking TDP-43 aggregation, suggesting that nuclear depletion of TDP-43 precedes 
cytoplasmic aggregation (Sun et al. 2017). 
 
As expected, the majority of IBM patient biopsies and none of the control patient 
biopsies showed cryptic exon expression. In addition, cryptic exon expression was 
detected within 8-month and 10-month IBM xenografts from three different IBM cases, 
but not in non-myositis control xenografts. Interestingly, cryptic exon incorporation is not 
observed in 4-month IBM xenografts, but is detected 8 months after the xenograft 
surgery suggesting this phenotype develops over time. It has been reported that TDP-43 
has a role in normal muscle regeneration through the formation of cytoplasmic, amyloid-
like “myo-granules,” which associate with sarcomeric mRNAs and localize to sites of 
sarcomere formation (Vogler et al. 2018). These myo-granules form in healthy muscle 
following injury and are readily cleared as myofibers matures. However, purified myo-
granules can seed the formation of amyloid-like fibrils in vitro (Vogler et al. 2018). It is 
hypothesized that the normal formation and resolution of these myo-granules is 
disturbed in muscle disease, leading to the formation of stable aggregates, which may 
drive disease pathology (Cutler et al. 2019). The potential role these myo-granules play 




in the development of IBM is an intriguing avenue for future studies with this xenograft 
model.  
 
In addition to these degenerative features, IBM xenografts also show mitochondrial 
pathology in the form of significantly elevated numbers of COX-deficient fibers, as well 
as endomysial inflammation. IBM xenografts show elevation of MHC-I, which 
corresponds to the presence of CD3+ T cells within IBM xenografts. In addition, 
examples of primary invasion of non-necrotic fibers are observed in xenografts from 
several different IBM patients, but invasion is not observed in xenografts from myositis 
control patients despite showing similar levels of endomysial inflammation. Further  
studies reveal that T cells in IBM xenografts are proliferative, antigen-experienced, and 
oligoclonal, which mirror immune cell populations described in IBM patients (reviewed 
in:Greenberg 2019). The antigen or multiple antigens driving the clonal expansion of T 
cells in IBM patients are still unknown. The xenograft model may enrich for these clonal 
populations and facilitate antigen discovery.  
 
Overall, our xenograft model of IBM is the first comprehensive laboratory model of the 
disease to model both degenerative and inflammatory features of the disease and 
represents a significant step forward in IBM research.  
 
The IBM xenograft model can be used for mechanistic studies and pre-clinical 
testing 
Based on recent successes with patient-derived tumor xenograft models, we 
hypothesize that treatment efficacy results in our IBM xenograft model are more likely to 
translate to trials in patients than in vitro models or mouse models of IBMPFD (Kim et al. 




2005; Rubio-Viqueira and Hidalgo 2009; Sako et al. 2010; Roberts et al. 2014; Ahmed et 
al. 2016; Izumchenko et al. 2017). Due to the extensive endomysial inflammation 
present in IBM xenografts including examples of primary invasion, we aimed to 
determine if reducing this inflammation would have an impact on the features of IBM 
pathology observed in this model. 
 
Although proponents of a primarily degenerative pathomechanism of IBM point to the 
lack of effectiveness of immunomodulatory therapies in IBM, there are a few clinical 
trials that suggest T cell ablation can benefit IBM patients. A pilot trial of alemtuzumab, a 
humanized monoclonal antibody targeting CD52 present on lymphocytes, was 
performed in 13 IBM patients and suggested that progression of weakness was reduced 
and that post-treatment biopsies showed a reduction in endomysial lymphocytes 
(Dalakas et al. 2009).  However, this study is controversial and the conclusions have 
been challenged (Greenberg 2010a). In addition, dual treatment with anti-T lymphocyte 
globulin (ATG) and methotrexate in a small patient population showed statistically 
significant efficacy in comparison to treatment with methotrexate alone (Lindberg et al. 
2003). It is also worth noting several studies have found that intravenous 
immunoglobulin (IVIG) may be beneficial for patients with dysphagia (Dalakas et al. 
1997; Dobloug et al. 2012). Thus, depletion of T cells continues to be a possible 
therapeutic strategy. 
 
Our initial attempts to remove inflammatory cells via ex vivo irradiation proved to be 
detrimental to control xenografts. Therefore, a more targeted approach using a 
monoclonal CD3 antibody (OKT3) was adopted. OKT3 binds to the epsilon chain of 
CD3, effectively blocking T cell receptor function and causing ablation of T cells in vivo 




following treatment (Norman 1995; Kjer-Nielsen et al. 2004; Wunderlich et al. 2014). 
OKT3 treatment significantly reduced T cells in IBM xenografts, but this did not impact 
xenograft regeneration or fiber morphology. One of the more striking findings of these 
OKT3 experiments was the positive relationship between the number of COX-deficient 
fibers and the number of T cells in IBM xenografts, which has also been observed in 
patient biopsies (Rygiel et al. 2015). This relationship was not observed in control 
xenografts, and this phenotype could be significantly ameliorated by ablating T cells with 
OKT3. To our knowledge, this is the first demonstration that T cells are driving 
mitochondrial pathology in IBM. Our data is also supported by recent work showing that 
exposing primary myotubes derived from non-myopathic patient samples to pro-
inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-1beta (IL-1β) 
can result in decreased COX protein levels (Chinoy and Lilleker 2019: P123). This is an 
exciting step forward in IBM research and demonstrates this xenograft model of IBM can 
be used to carry out mechanistic studies to better understand disease pathogenesis and 




Moving forward, our immediate goals are to fully characterize the human immune cells 
present within IBM xenografts, to compare xenografts to patient biopsies using RNA-
sequencing (RNA-seq), and to better understand the dynamics underlying cryptic exon 
expression. We will be expanding on the TCR sequencing data by analyzing our patient 
biopsies and comparing them to xenografts. We hypothesize that all the xenografts from 
a single patient will be enriched for a subset of T cell clones shared with the original 
biopsy if the observed proliferation is antigen driven. Alternatively, xenografts from the 
same patient may show variable populations of T cells more indicative of a bottleneck. In 




addition, flow cytometry will allow us to better understand the specific subsets of immune 
cells present within the xenografts. We have been able to show that IBM xenografts 
contain both CD8+CD57+ and CD4+CD57+, antigen experienced cells. Recently, highly 
differentiated, cytotoxic KLRG1+ T cells have been proposed as a potential therapeutic 
target in IBM (Greenberg et al. 2019), and our preliminary data show KLRG1+ T cells 
within xenografts. We aim to assess if this population of cells is affected by OKT3 
treatment using flow cytometry and immunohistochemistry.  Going forward, we are 
obtaining peripheral blood mononuclear cells (PBMCs) from patients at the time of 
biopsy so that we can compare the antigen-specificity and function of T cells from patient 
blood with those present in the biopsied muscle and xenograft.   
 
It will be informative to examine the subsets of nonlymphocytic cells as well. For 
instance, it has been recently reported that CD74, CD163, and STAT1 are highly 
expressed in muscle biopsies of sIBM patients and these proteins were found to localize 
to macrophages (Roos et al. 2019). We are currently assessing different populations of 
human immune cells including macrophages, B cells, NK cells, and dendritic cells in all 
our xenograft experiments as we have done previously.  Another interesting area to 
explore in the future is the role of the host (mouse) innate immune system in muscle 
regeneration in the xenograft model. Our preliminary flow cytometry experiments  
performed in collaboration with the Villalta laboratory suggest that there are many mouse 
macrophages present within the human xenografts, presumably to phagocytose 
degenerating human myofibers, but the role  that they are playing in both control and 
IBM xenografts is unknown.  
 




Recent RNA sequencing of myositis patients has shown activation of the interferon 1 
(IFN1) pathway in patients with DM, antisynthetase syndrome (AS), IMNM, and IBM, as 
well as robust activation of the interferon 2 (IFN2) pathway in AS, IBM, and DM but not 
in IMNM (Pinal-Fernandez et al. 2019). In addition, a study comparing Jo-1 associated 
myositis patients to IBM patients using RNA sequencing followed by pathway analysis 
found the top canonical pathways altered in both Jo-1 and IBM were oxidative 
phosphorylation and mitochondrial dysfunction (Hamann et al. 2017). These studies 
demonstrate the usefulness of using transcriptomic analysis to understand similarities 
and differences between subsets of myositis, and to identify biological pathways of 
interest. We aim to perform RNA sequencing to compare xenografts with the initial 
muscle biopsy to determine how closely xenografts resemble the initial biopsy and to 
characterize cytokine expression and determine if there are any muscle-specific 
changes in gene expression. 
 
In addition, we will expand our understanding of the dynamics underlying cryptic exon 
expression by analyzing additional xenograft samples and timepoints. Currently, it 
appears that only biopsies with cryptic exon expression result in xenografts with cryptic 
exon expression. We do not yet know whether the variability in cryptic exon detection is 
due to assay variability, heterogeneity of muscle biopsies, or whether the presence or 
absence of cryptic exon detection or defines specific subtypes of IBM.  If the latter, 
cryptic exon detection may be a useful disease biomarker and may suggest that there is 
a factor intrinsic to the skeletal muscle niche regulating TDP-43 pathology. Our data also 
indicate that cryptic exon incorporation is only detectable at late timepoints, although we 
have yet to fully examine the time course of cryptic exon expression. In addition, it is 
possible that there is earlier expression, but that our RT-PCR assay is not sensitive 




enough to detect it. Ligation in situ Hybridization (LISH) is a technique we plan to use for 
more sensitive detection of cryptic exons, and we may potentially adapt LISH to visualize 
cryptic exons within patient biopsies and xenograft samples (Credle et al. 2017). This 
method uses T4 RNA Ligase 2 to efficiently join adjacent chimeric RNA–DNA probe 
pairs hybridized in situ on fixed RNA target sequences, which allows for multiplexed 
measurement of multiple targets and would allow us to analyze several TDP-43 target 
genes simultaneously.  
 
Finally, although the dramatic reduction of inflammatory cells via OKT3 did not 
significantly improve regeneration, these samples allow us to examine about how the 
presence of lymphocytes in IBM muscle impact some of the pathological phenotypes 
we’ve observed in the IBM xenograft model. Beyond the exciting results showing the role 
of inflammation in mitochondrial pathology, we also want to test how eliminating T cells 
impacts cryptic exon expression within xenografts. These experiments will help advance 
our understanding of how the immune system influences IBM pathology.
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